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Abstract
Sickle cell disease (SCD) is caused by a mutation of the β-globin gene (HBB), resulting in abnormal
hemoglobin molecules that polymerize when deoxygenated, forming “sickle” shaped red blood cells
(RBCs). Sickle RBCs lead to anemia, multi-organ damage and pain crises, beginning the first year of life.
The onset of symptoms coincides with the developmental switch of β-like globin gene expression from
fetal stage γ-globin to adult stage β-globin, resulting in a shift from fetal hemoglobin (HbF, α2γ2) to adult
hemoglobin (HbA, α2β2). Some individuals harbor rare genetic variants in the extended β-globin gene
cluster that cause constitutively elevated postnatal HbF, a benign condition known as hereditary
persistence of fetal hemoglobin (HPFH) which alleviates symptoms of co-inherited SCD. Previously, we
showed that CRISPR-Cas9-mediated genome editing can recreate a naturally occurring HPFH variant in
the γ-globin (HBG1 and HBG2) promoters. Disruption of a TGACC nucleotide motif within this region by
Cas9-mediated non-homologous end joining in human erythroid cells or their progenitors caused
induction of HbF by interfering with recruitment of the transcriptional repressor, BCL11A. This strategy
results in potent HbF induction in human cells and is a promising therapeutic strategy. However, the
efficiency of genome editing and the level of HbF induction required to arrest or reverse the pathologies of
SCD are unknown.
In this work, we investigated the utility of humanized mouse models for SCD to answer this question. We
further characterized the genomic configurations of two models: Berkeley mice, which harbor multiple
tandem copies of three separate transgenes encoding human α-globin, sickle β-globin (βS) and a
segment of the locus control region (LCR) a powerful enhancer that drives high-level erythroid-specific
expression of linked genes; and Townes mice, in which the endogenous α-globin gene is replaced by the
homologous human gene and the endogenous β-globin gene is replaced by human γ-globin (γA) and βSglobin genes. Genome editing of human γ-globin promoter in the Berkeley mouse induced a massive DNA
damage response and cell death caused by the accumulation of multiple double-stranded DNA breaks
(DSB) within the highly repetitive human transgene. In contrast, it was possible to achieve high-level
editing of the single copy human γ-globin gene in the Townes model. However, induction of HbF was
approximately 10-fold less that what occurred after generating the same edits in human cells, possibly
because the mouse model lacks essential non-coding DNA regulatory sequences. Together, these
limitations rule out the Berkeley mouse for DSB-inducing gene-editing purposes and the Townes mouse
for HbF induction by regulatory element targeting.
Despite these limitations, we determined the Townes model to be a good candidate for a base editing
strategy to directly alter the SCD mutation. This work sought to edit the sickle T to a G, resulting in the Hb
G-Makassar variant suspected to be benign and non-sickling. Recipient mice transplanted with
successfully edited (55-60%) Townes HbSS Lin- cells show marked improvement in blood count values
and splenomegaly. This Hb G-Makassar strategy allows for a better understanding of the levels of
hematopoietic stem cell editing required to correct the SCD phenotype.
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ABSTRACT
Sickle cell disease (SCD) is caused by a mutation of the β-globin gene (HBB),
resulting in abnormal hemoglobin molecules that polymerize when deoxygenated,
forming “sickle” shaped red blood cells (RBCs). Sickle RBCs lead to anemia, multiorgan damage and pain crises, beginning the first year of life. The onset of symptoms
coincides with the developmental switch of -like globin gene expression from fetal stage
γ-globin to adult stage β-globin, resulting in a shift from fetal hemoglobin (HbF, α2γ2) to
adult hemoglobin (HbA, α2β2). Some individuals harbor rare genetic variants in the
extended β-globin gene cluster that cause constitutively elevated postnatal HbF, a benign
condition known as hereditary persistence of fetal hemoglobin (HPFH) which alleviates
symptoms of co-inherited SCD. Previously, we showed that CRISPR-Cas9-mediated
genome editing can recreate a naturally occurring HPFH variant in the γ-globin (HBG1
and HBG2) promoters. Disruption of a TGACC nucleotide motif within this region by
Cas9-mediated non-homologous end joining in human erythroid cells or their progenitors
caused induction of HbF by interfering with recruitment of the transcriptional repressor,
BCL11A. This strategy results in potent HbF induction in human cells and is a promising
therapeutic strategy. However, the efficiency of genome editing and the level of HbF
induction required to arrest or reverse the pathologies of SCD are unknown.
In this work, we investigated the utility of humanized mouse models for SCD to
answer this question. We further characterized the genomic configurations of two
models: Berkeley mice, which harbor multiple tandem copies of three separate transgenes
encoding human -globin, sickle -globin (S) and a segment of the locus control region
(LCR) a powerful enhancer that drives high-level erythroid-specific expression of linked
genes; and Townes mice, in which the endogenous -globin gene is replaced by the
homologous human gene and the endogenous -globin gene is replaced by human globin (A) and S-globin genes. Genome editing of human -globin promoter in the
Berkeley mouse induced a massive DNA damage response and cell death caused by the
accumulation of multiple double-stranded DNA breaks (DSB) within the highly repetitive
human transgene. In contrast, it was possible to achieve high-level editing of the single
copy human -globin gene in the Townes model. However, induction of HbF was
approximately 10-fold less that what occurred after generating the same edits in human
cells, possibly because the mouse model lacks essential non-coding DNA regulatory
sequences. Together, these limitations rule out the Berkeley mouse for DSB-inducing
gene-editing purposes and the Townes mouse for HbF induction by regulatory element
targeting.
Despite these limitations, we determined the Townes model to be a good
candidate for a base editing strategy to directly alter the SCD mutation. This work sought
to edit the sickle T to a G, resulting in the Hb G-Makassar variant suspected to be benign
and non-sickling. Recipient mice transplanted with successfully edited (55-60%) Townes
HbSS Lin- cells show marked improvement in blood count values and splenomegaly.
This Hb G-Makassar strategy allows for a better understanding of the levels of
hematopoietic stem cell editing required to correct the SCD phenotype.
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CHAPTER 1.

INTRODUCTION

Hemoglobin

The hemoglobin tetramer
Hemoglobin is a tetrameric molecule within red blood cells (RBCs) whose main
function is to carry oxygen (O2) to the tissues throughout the body. The tetrameric
structure includes four globin protein subunits (two -like and two -like) each
containing an iron atom bound to a heme prosthetic group which facilitates the binding
and release of O2.1,2 The formation of hemoglobin requires balance of globin gene
expression to prevent the formation of - or -globin aggregates and resulting cytotoxic
effects like production of reactive O2 species (ROS).3 To prevent such toxicities,
chaperones like -hemoglobin stabilizing protein (AHSP) work to bind -globin subunits
until the appropriate -globin subunits are produced.4,5 Biological examples of how
globin chain imbalance can have disastrous effects are found in patients with - or thalassemia, a disorder caused by mutations or deletions affecting globin gene
expression.6
The tetrameric structure of hemoglobin and the chemical bonds that hold the four
globin subunits and heme together play a major role in facilitating the conformational
changes that allow for the binding and release of O2. An - dimer forms first, through
the formation of a high affinity interaction (11 interface), followed by the completion
of the tetramer through weaker interactions (12 interface) (Figure 1-1).7 Upon the
binding of the first O2 molecule, a confirmational change from the deoxygenated (T or
“tense”) state to the oxygenated (R or “relaxed”) state enhances cooperativity of
hemoglobin and allows for the remaining O2 molecules to bind.2,8 The reversible T to R
conformational change relies on the interactions between select amino acid residues (e.g.
proximal histidine, covalently bound to iron).9 Hemoglobin variants (discussed in later
sections) that result in mutations in these crucial amino acids can affect 11 and 12
interactions or O2 affinity leading to larger pathological consequences like anemia.7
The β-globin locus and its regulation
The individual globin subunits are encoded by two distinct loci, each of which
harbor multiple paralogous spatially and developmentally regulated globin genes: the globin locus at hChr16 and the -globin locus at hChr11.10 The functionally similar
globin genes within these loci are expressed at different times during human
development, an effect known as hemoglobin switching.11,12 The -globin locus is home
to HBZ (zeta) expressed in the embryonic stage and HBA1 and HBA2 (alpha, α)
expressed in the fetal and adult stages. The β-globin locus is home to five paralogous βlike genes: HBE1 (epsilon, ε) expressed in the embryonic stage, HBG2 and HBG1
(gamma, G, A) expressed during fetal development, and adult globins HBD (delta, δ)
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Figure 1-1. Hemoglobin tetramer structure and interactions between subunits.
The hemoglobin tetramer is formed from the high affinity interface (11) between
unlike subunits and brought together by a lower affinity tetramer interface (12).
Reprinted with permission. Thom, C. S., Dickson, C. F., Gell, D. A., & Weiss, M. J.
Hemoglobin variants: Biochemical properties and clinical correlates. Cold Spring Harbor
Perspectives in Medicine, 3(3). (2013). https://doi.org/10.1101/cshperspect.a011858.7
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and HBB (beta, β) expressed after a completed hemoglobin switch at approximately six
months after birth (Figure 1-2A, B).
The β-globin locus is developmentally controlled by a complex mechanism that
utilizes both spatial regulation through chromatin looping and the cis-regulatory
machinery of activators and repressors.13 Upstream of the β-globin genes are a set of five
DNase I hypersensitive sites (HS) referred to as the “locus control region” or LCR.14–16
The LCR acts as an enhancer of expression of the β-globin locus. Chromatin looping of
HS-5 with a 3’ HS downstream of the β-globin gene further aids in expression of the βglobin genes.17,18 Many transcription factors work as positive or negative regulators to
control gene expression of the various globin genes, either directly, or by stimulating the
formation of specific chromatin loops.13 BCL11A, one of the most potent transcription
factors involved in the fetal to adult hemoglobin switch, acts to repress γ-globin
expression allowing for β-globin to be expressed.19,20 Similarly, LRF or ZBTB7a acts as
the second strongest regulator of -globin, and has been shown to bind to the -globin
promoter.21,22
Genetic variants throughout the β-globin locus
Many mutations, deletions, and single nucleotide polymorphism (SNPs) have
been identified throughout the β-globin locus.23 These mutations range from disease
causing to completely benign, as well as some beneficial mutations that can improve
phenotypes when coinherited with certain genetic diseases.23,24 Here we overview
hemoglobin variants (specifically Hemoglobin S and Hemoglobin G-Makassar), and
mutations and deletions resulting in hereditary persistence of fetal hemoglobin (HPFH).
Hemoglobin variants
Over 1000 hemoglobin variants have been identified within the coding sequences
of the globin genes, most of which are missense single amino acid substitutions that alter
the structure and function of hemoglobin.24 While many of these are rare variants found
within a small subset of individuals, others like Hemoglobin S or Hemoglobin E are more
prevalent and represent a significant global burden.
Hemoglobin S, “sickle” hemoglobin. One of the most common, well-studied
pathological hemoglobin variants, Hemoglobin S (HbS), is caused by a single point
mutation in the sixth codon of the β-globin gene, resulting in sickle cell disease (SCD).25
SCD encompasses a group of disorders where HbS contributes to disease pathology
either alone as a homozygous mutation (HbSS), co-inherited with other variants (i.e.
HbSC, HbSE) or deletions (HbS-β+ or HbS-β0 thalassemia).23 The HbS mutation causes
an amino acid alteration from glutamic acid to valine (Glu6Val) which results in a
structural change that leads to polymerization of hemoglobin molecules under low O2
tension (deoxygenated, T or “tense” state).26,27 The mutant hydrophobic valine (6Val,
nomenclature indicates the sixth codon of the -globin subunit that is a Valine) on one

3

Figure 1-2. Human β-globin locus and the γ to β-globin gene switch.
(A) The human β-globin locus at hChr11 is shown. Relevant long non-coding RNAs and
pseudogenes are shown in gray, while developmentally expressed genes are shown as
blue (embryonic), green (fetal), and red (adult). Hypersensitive sites are indicated as
black arrows. (B) The hemoglobin switch from conception to six-months post-birth.
Reprinted with permission. Sankaran, V. G. & Weiss, M. J. Anemia: Progress in
molecular mechanisms and therapies. Nat. Med. 21, 221–230 (2015).10
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-globin subunit, a pattern that repeats in low O2 conditions and forms long polymers.
(Figure 1-3).27–29 Polymerized hemoglobin causes elongation of the RBC and results in
the “sickle” shape associated with the disease.25 The hemolytic anemia and vasoocclusive crises responsible for much of the disease presentation can be attributed to
sickled, unhealthy RBCs.29 Additionally, the SCD allele is common in African
individuals due to genetic selection because heterozygosity (SCD) trait confers resistance
to malaria.30
Due to polymerization of hemoglobin, RBCs are stretched and weakened,
resulting in brittle sickled cells. Sickle RBCs are either directly or indirectly responsible
for most of the symptoms and pathophysiology associated with the disease. Sickle RBCs
stick together within the microvasculature causing vaso-occlusive crises as well as
hemolysis, releasing toxic free hemoglobin into the bloodstream.31 These events, over
time, result in long term organ damage and ultimately lead to premature death for
patients. The vaso-occlusive crises caused by sickled cells leads to major pathological
effects on nearly every organ in the human body. Much of the damage results from
ischemia, lack of blood and O2 in organs, and reperfusion injury, the tissue damage that
occurs after rapid replenishing of blood to organs.32
Hemoglobin G-Makassar. Hb G-Makassar is a rare hemoglobin variant that was
first identified in 1969 in Makassar, Indonesia and has since been identified in a few
patients in Southeast Asia. This variant is a missense mutation at the sixth codon of the globin gene that results in conversion of glutamic acid to alanine (Glu6Ala), a smaller
hydrophobic residue than the pathogenic valine substitution in HbS. In fact, this smaller
alanine residue does not seem to contribute to hemoglobin polymerization given that Hb
G-Makassar patients have normal hematological parameters and exhibit no sickling of
RBCs.33,34 Studies comparing HbS and Hb G-Makassar are made complicated by roughly
equivalent migration times on ion exchange HPLC and hemoglobin electrophoresis,
rendering the two variants almost identical by these techniques.33 In this dissertation,
base-editing technology is utilized to alter the SCD mutation to the Makassar mutation to
study its effect on disease pathology (Chapter 4).35,36
Hereditary persistence of fetal hemoglobin
Unlike hemoglobin variants that affect the structure and function of the globin
subunits, there are many mutations found throughout the extended -globin locus that
affect globin gene expression.37 This work focuses on some of the HPFH mutation that
repress the normal postnatal silencing of -globin or fetal hemoglobin (HbF, 22)
expression.38 HPFH encompasses deletional (large deletions of entire globin genes, as
well as small deletional mutations) and nondeletional (SNPs of regulatory elements and
transcription factor binding sites) mutations that disrupt normal globin regulation.
Inheritance of any mutation that increases HbF alongside the HbS mutation prevents the
onset of some of the more severe symptoms of the disease.38 This effect is due to the fact
that the HBG1 and HBG2 genes, and resultant HbF tetramers, are unaffected by the SCD
mutation and also because the g-globin protein has anti-sickling effects when
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Figure 1-3. Formation of hemoglobin polymers as a result of the SCD mutation.
The formation of hemoglobin polymers results from the Glu6Val mutation in the globin subunit, and its interaction with neighboring hemoglobin molecules. Reprinted
with permission. Odièvre, M. H., Verger, E., Silva-Pinto, A. C., & Elion, J.
Pathophysiological insights in sickle cell disease. Indian Journal of Medical Research,
134(10), 532–537 (2011).29
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co-expressed with HbS.39 Indeed, SCD patients with elevated HbF levels have been
shown to have an increased probability of survival further proving the benefits of fetal
globin gene expression into adulthood.40
Due to the “anti-sickling” effect of HbF, its induction has become a major target
of therapies for SCD including those which seek to recreate specific HPFH mutation.41
One of the most potent nondeletional HPFH mutations is a 13 nucleotide (nt) deletion
found in the HBG1 promoter that leads to approximately 30% HbF in heterozygous
individuals.42 We recently recreated this mutation by clustered regularly interspaced short
palindromic repeats (CRISPR)/Cas9 gene editing in an erythroid cell line and measured a
significant induction of HbF (Figure 1-4).43 Through further investigation it was
discovered that BCL11A binds to the region of the promoter that was deleted in the 13 nt
HPFH mutation, a primary event necessary for the repression of γ-globin during the
hemoglobin switch.44

Gene-Based Cell Therapies

Gene therapy
Gene therapy encompasses therapeutic strategies for diseases that involve an
addition or amendment to the genetic code.45 Since the early 1970s, gene transfer
strategies have been explored for the purposes of introducing functional genes to offset
the effect of a disease causing mutation or deletion.46 These strategies have developed
overtime to encompass viral and non-viral methods to facilitate gene augmentation or
suppression based on the disease mechanism (Figure 1-5).47,48 Gene augmentation
leverages gene transfer to functionally correct the presence of a gene defect, while gene
suppression works to decrease the expression of an undesired gene by RNA
interference.47 Additionally, gene editing strategies using a nuclease to make specific
changes in the genome is outlined in the next section.

Gene editing and CRISPR/Cas9
Gene editing is a gene-based therapy that utilizes programmable DNA binding
proteins to allow for site-specific targeting of the genome.49 There are multiple types of
nucleases used for gene editing: zinc-finger nucleases (ZFNs), transcription activator-like
effector nucleases (TALENs), meganucleases and CRISPR/Cas9.50,51 This dissertation
utilizes CRISPR/Cas9 technology, the mechanism of which is summarized below.
In prokaryotes, CRISPR and CRISPR-associated proteins (Cas) act in an adaptive
immune response to foreign genetic elements, primarily as a defense against
bacteriophages.52 This immunity allows for organisms to remember and detect a

7

Figure 1-4. Gene editing strategy to recreate a naturally occurring 13nt HPFH
mutation that causes elevated HbF in patients.
The location of the 13 nucleotide HPFH mutation found in patients.42 The TGACC sites
are indicated by the gray hashed boxes, BCL11A binds to the distal (-115) CCAAT box.
These sites also represent two direct repeats that, through microhomology-mediated end
joining (MMEJ), are likely responsible for the formation of a deletion of that size. The
gRNA is indicated, with the protospacer adjacent motif (PAM) in red, arrows indicate
hypersensitive sites.

8

Figure 1-5. Various approaches to correction of a gene defect by gene therapy.
(A) Gene augmentation by gene transfer of a functional gene to offset the original gene
defect. (B) Gene suppression by introduction of an miRNA or shRNA inhibitory
sequence to shut down the undesired gene. Reprinted with permission. Anguela, X. M., &
High, K. A. Entering the modern era of gene therapy. Annual Review of Medicine, 70,
273–288. (2019). https://doi.org/10.1146/annurev-med-012017-043332. 47

9

previously seen pathogen, then respond by deploying nucleases that seek out the
pathogen in a DNA sequence-specific manner.53,54 Taking advantage of this mechanism
allows for a guide RNA (gRNA) to find any desired DNA sequence, provided it has an
available protospacer adjacent motif (PAM) sequence, to be targeted and cut by the
endonuclease.55 The double-strand breaks (DSB) created by the Cas9 proteins are then
healed by endogenous cellular DNA repair mechanisms. The predominant repair
mechanism, non-homologous end joining (NHEJ), is an error-prone mechanism that
usually results in small base pair insertions or deletions (indels).56 Alternatively, if a
DNA template is available, the DSBs may be corrected using base pair homology
between the template and the targeted genomic region. This mechanism, termed
homology directed repair (HDR) is more precise but occurs less frequently than NHEJ.56
Another less frequent mechanism, microhomology mediated end joining (MMEJ) takes
advantage of short repeats near the DSB to use as homology and often results in a small
deletion of the sequence between the repeats.56
The two major mechanisms above for repair of DSBs can be leveraged with
CRISPR/Cas9 technology to allow for specific kinds of gene edits. Loss of gene function
can be achieved by DSBs and random indel creation in a crucial coding element.
Correction of a mutation can occur with HDR in the presence of a suitable homologous
template sequence. Together, CRISPR/Cas9 represents a flexible gene editing technique
that will be utilized within this work.
Importantly, gene editing proteins and gRNAs can be delivered into cells through
several mechanisms—a fact that is crucial to the success and development of preclinical
therapies (Figure 1-6). As mentioned previously, viral vectors can deliver and integrate
genes encoding editing materials into the genome.57,58 On the other hand, transient gene
editing using ribonucleoprotein (RNP), consisting of gRNA complexed to Cas9 protein,
is commonly used to deliver editing materials into the cell in a more temporary manner
that does not integrate any machinery into the host genome.57 Plasmid DNA and mRNA
can also be used as a format for delivering gene editing nucleases into a cell.57 Proteins,
DNA or RNA can be introduced into cells by electroporation (or directly into a nucleus
by nucleofection), by nanoparticles, and by lipofection (by liposomes).48,57

Approaches to Treating Sickle Cell Disease
SCD is the oldest characterized monogenic disease giving rise to many research
groups who devote their time and expertise to finding cures.59 The ways in which these
groups have approached therapies for SCD varies and has changed over time. Overall, the
approaches for curing SCD can be broken down into three themes: 1) correction of the
sickle mutation, 2) gene addition of “anti-sickling” globins to offset the presence of sickle
globin, and 3) targeting of regulatory elements responsible for repression of -globin to
induce HbF levels.60 The rationale of each of these approaches and a review of relating
preclinical work is addressed in the sections below (Figure 1-7).
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Figure 1-6. Strategies for cellular therapies.
In vivo and ex vivo strategies for improving disease outcomes. Reprinted with
permission. van Haasteren, J., Li, J., Scheideler, O.J. et al. The delivery challenge:
fulfilling the promise of therapeutic genome editing. Nat. Biotechnol. 38, 845–855
(2020).48
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Figure 1-7. Approaches to treating SCD.
The three main approaches to curative therapies for SCD are correction of the SCD
mutation by HDR or base editing, gene addition by viral gene transfer of a healthy βglobin gene or γ-globin gene, and HbF induction by targeting γ-globin repressors or
binding sites.
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Mutation correction
Perhaps the most obvious approach to treating SCD would be correction of the
sickle mutation. The relevant gene editing approach leverages the HDR pathway after a
cell experiences a targeted DNA DSB by a homing endonuclease such as Cas9. allowing
for a corrected template, provided by an exogenous oligonucleotide, to be integrated in
place of the mutation.61 While this approach has great potential, the efficiency of HDRmediated repair remains low even after optimal editing conditions are ascertained and
will require more research to improve HDR rates.62,63 In a recently successful example of
this strategy, an HDR rate of 24.5 ± 7.6% correction was achieved with SpyCas9, gRNA
and a single stranded oligonucleotide template in SCD patient CD34+ cells.61 Recent
base-editing technology provides additional tools for mutation correction strategies and
some advantages over HDR. HDR is most efficient at S and G2 phases of the cell cycle, a
limitation that doesn’t appear to plague base editing technology.64 In addition, HDR is
often associated with increased rates of undesired indels that are not as frequent in base
editing when not relying on DSBs.64 An alternative approach to mutation correction
could be mutation “replacement” or altering the mutation to one with potentially fewer
toxic effects when correction is not a viable option. An example would be using baseeditor technologies to change the sickle mutation to the previously discussed Hb G
Makassar mutation (Glu6Ala), which has not been shown to cause hemoglobin
polymerization. Recent work outlining this strategy is addressed in Chapter 4 of this
dissertation.36

Gene addition
Gene addition strategies have shown great promise by adding “anti-sickling” like globins offset the effect of the sickle β-globin.65 Multiple groups have optimized
viral vectors that focus primarily on modified β-globins and/or γ-globin addition, some of
which have gone on to clinical trials.66–71 These viral vectors, mainly lentiviral, contain
an anti-sickling -like globin gene and portions of the LCR and gene promoters to drive
expression of the inserted gene.66,72
One example of gene addition products in clinical trials comes from of bluebird
Bio known as LentiGlobin (BB305).73 This lentivirus harbors a healthy β-globin gene
that has been mutated to cause a T87Q amino acid substitution.73 Given the limited
differences in the γ and β-globin gene sequences, residue 87 was determined to be
responsible for much of the anti-sickling properties of γ-globin so that the T87Q mutation
in the β-globin inhibits polymerization of sickle hemoglobin73,74. Furthermore, the
biochemical properties of A-T87Q are distinct and can be specifically measured by HPLC
due to different electrophoretic mobilities compared to wild-type -globin.70 This
strategy has shown continued expression of the A-T87Q as well as improvements in
hemoglobin levels for both SCD patients and transfusion-dependent β-thalassemia
patients.
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HbF induction
As stated earlier, the improved disease phenotype in SCD patients with elevated
HbF levels provides proof of HbF induction as a therapeutic target.41,75 HbF levels
between 20-30% are thought be therapeutic against SCD based on clinical observations
of individuals with both mutations.40,76 HbF induction strategies include but are not
limited to: 1) targeting of γ-globin repressors, e.g. BCL11A, 2) disruption of binding sites
of such repressors within the HBG genes and 3) forced chromatin-looping to activate γglobin expression.17,43,77,78
The aforementioned 13 nucleotide HPFH mutation that overlaps a BCL11A
binding site is a prime candidate for HbF induction as a therapeutic strategy, and this
work will delve into such a therapy.44 In addition to binding site disruption, great success
has been seen by reducing BCL11A protein levels through disruption of the critical
erythroid-specific BCL11A enhancer responsible for much of its expression in RBCs and
knockdown of BCL11A mRNA through RNA interference.77,79 Both strategies have
demonstrated heightened HbF levels in SCD patient CD34+ cells in culture, and a marked
improvement in sickling under hypoxia or drug-induced sickling assays77,78.

Use of Mouse Models
In vivo validation of potentially therapeutic targets is a crucial step in moving a
strategy towards clinical trials. Mouse models act as a cost-effective means for testing
such strategies in a genome that is similar to the human genome.80 The use of
“humanized” mice with human globin genes as well as immunocompromised models that
can be reconstituted with human bone marrow are valuable tools in preclinical testing and
will be addressed in this dissertation.

Mouse xenograft models
Xenotransplantation is defined as the process of grafting cells, tissues or organs
between two species. The first examples of performing a xenotransplantation of human
cells into immunocompromised mice began in the late 1980’s; however, it wasn’t until
1992 when the CD34+ cell population (hematopoietic progenitors and stem cells) were
introduced into immunocompromised mice.81 Infusion of a human population like CD34+
cells allows for engraftment of hematopoietic stem cells (HSCs) and the subsequent
creation of human bone marrow progeny.
Of the immunodeficient models available, NOD scid gamma (NSG) models and
their derivatives are some of those most commonly used for human cell engraftment
studies. The background NOD strain, NODShiLtJ, was used for its decreased innate
immunity and Sirpa allele which renders the bone marrow niche very susceptible to
reconstitution by human HSCs.82,83 NSG mice harbor a Prkdcscid mutation preventing
functional Prkdc expression which aids in DNA repair in somatic recombination of T cell
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receptor and immunoglobulin genes.84 This mutation, originally seen in patients with
severe combined immune deficiency (SCID), results in the absence of functional T and B
cells and allows for reconstitution of implanted cells without a host immune response.
Additionally, the IL2 receptor γ chain (IL2rgnull) was mutated to further improve immune
deficiency by preventing cytokine signaling through multiple receptors preventing
functional natural killer cells.85 These mutations and background combination result in
the commonly used NSG model which is well known for being highly immune deficient
and capable of being reconstituted with human cells.
Currently, studies requiring the production of human RBCs prefer the use of the
NBSGW mouse, an NSG derivative. The primary goal in creating this model was to do
away with the necessary myeloablation required before transplantation of donor cells. By
crossing the NSG mouse with a C57BL/6J mouse harboring a c-Kit mutation (W41) that
prevents normal hematopoiesis, this mouse was capable of engrafting human donor
CD34+ cells without the need for irradiation.86 This mutation functions by allowing donor
HSCs to have a competitive advantage over the c-Kit mutant host, and successfully
engraft with little to no irradiation.87 In addition, this strain allowed for a higher
percentage of human cells in the bone marrow and importantly, the presence of human
erythroid cells which were not previously detected in NSG bone marrow.86 While being a
great improvement to previous models, the NBSGW mouse still lacks the ability to
produce circulating human RBCs and as a result cannot be used for organ or
pathophysiological studies for RBC disorders.

Mouse models of SCD
For physiological studies, a mouse model capable of demonstrating disease
severity is an advantageous tool. Efforts to create mouse models that recapitulate much of
the pathophysiology of SCD and human hemoglobin expression began in the 1990s.
Below, we address the genetics, phenotype and previous gene therapy applications of the
three most common mouse models used to test preclinical strategies for SCD.
Berkeley mouse
Genetics. In 1997, the “Berkeley” transgenic mouse model was published,
becoming the first of its kind to express exclusively human globins.88 The model was
created by pronuclear co-injection of three human fragments (mini-LCR, HBA1, and a 39
kilo-base pair (kb) fragment encompassing HBBS, HBD, HBG2, and HBG1 and intergenic
regions) allowing for random integration into the mouse genome (Figure 1-8 upper
panel). The resulting mouse was crossed with mice heterozygous for deletions of the
mouse α and β-globins resulting in a model that expressed exclusively human globin and
that mimicked human hemoglobin switching.
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Figure 1-8. Genetics of Berkeley and Townes mouse models of SCD.
(Upper panel) Three human transgenic fragments incorporated into the Berkeley mouse
transgene.88 (Lower panel) β-globin Townes knock-in. Small black arrows indicate the
hypersensitive sites, the large black arrow indicates the resultant genetic configuration
after the knock-in.89
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Phenotype. The Berkeley model continues to be one of the most pathologically
representative models of humans with the disease, being used primarily to study pain and
inflammation in SCD.90,91 Blood count analyses show that Berkeley mice exhibit severe
anemia and elevated reticulocyte count comparable to SCD patients.92 Organ pathology
within the model includes cardiomegaly and infarctions, splenomegaly, and severe
hepatic infarctions. The afflicted organs are similar to those in SCD patients, though
severity may vary. Of note, splenomegaly is a major characteristic of homozygous
Berkeley mice and possibly the most notable physical difference between homozygous
and Hbb+/- rescue littermates. While splenic complications are commonly associated with
SCD, permanent splenomegaly (as seen in the Berkeley model) is not as frequent in
patients as a splenic sequestration crisis, a temporary enlargement of the spleen due to
rapid RBC filtration.93 Regardless, this work and others use spleen weight as a key
indicator of disease severity. Additionally, Berkeley mice have increased heart and
kidney weights, kidney infarcts and fibrosis, vascular congestion in the lungs, and liver
infarcts from ischemic injury.88
Literature review of gene therapy applications. The Berkeley model has been
used to test gene addition and HbF induction strategies for SCD gene therapy, some of
which have gone on to clinical trials. In 2001, the Leboulch group used a lentiviral vector
to deliver a mutated β globin variant (βA-T87Q) designed to mimic the anti-sickling activity
of γ-globin to Berkeley mouse bone marrow cells66. The transduced bone marrow cells
were transplanted into recipient C57Bl/6 mice that showed a marked decrease in the
percentage of sickle RBCs, reticulocyte count and spleen weight. Derivations of this
vector (BB305 as mentioned above) have gone on to clinical trials for both β-thalassemia
and SCD.94 Two groups (Malik and Persons) published work in 2009 using the Berkeley
SCD mouse model to test lentiviral gene addition strategies for -globin.68,69 Both works
demonstrated an increase in HbF and corresponding decrease in sickle RBCs and spleen
weight. The sGbG lentiviral vector out of the Malik group has gone on show increase
HbF and improved clinical parameters in two S/0 patients in clinical trials.95,96 HbF
induction strategies by targeting γ-globin regulatory elements have also been validated in
the Berkeley model. The Orkin group demonstrated SCD phenotype correction after
crossing a Bcl11a erythroid-specific knockout model with the Berkeley mouse and
producing 85% F-cells.97 Overall, the Berkeley model has been used quite
comprehensively to test therapeutic strategies for SCD.
Townes mouse
Genetics. In 2006, a knock-in model of SCD was produced by Tim Towne’s
group89. This model is stated to include HBA1 in place of both endogenous mouse αglobin genes and sickle or healthy-HBB and HBG1 in place of both endogenous adult
mouse β-globin genes (Figure 1-8 lower panel). Plasmid constructs harboring the
desired human globin inserts flanked by the appropriate mouse homology sites were
electroporated into mouse ES cells. The ES cells were screened for the correct insert and
then injected into C57Bl/6 blastocysts. The resultant mice were further crossed until they
were homozygous for HBA1, HBG1 and sickle-HBB (HbSS). Of note, homozygous
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(HbAA) and heterozygous (HbAS) healthy-HBB mice were created and used as controls
and breeding partners.
Phenotype. The Townes mouse recapitulates some of the pathophysiology of
SCD. Blood smears from HbSS Townes mice show the presence of elongated sickle
cells, poikilocytosis (abnormally shaped RBCs), anisocytosis (abnormally sized RBCs),
polychromasia and reticulocytosis which are commonly seen in SCD patients.
Hematologic values of the HbSS mice are representative of the patient phenotype:
decreased RBC count, decreased hemoglobin, increased RDW% and increased MCV. Of
note, HbAA and HbAS mice demonstrate improved or “corrected” blood smears and
hematologic parameters. Organ histology of HbSS animals similarly shows a decrease in
organ health of the spleen (severe splenomegaly), liver (necrosis and extramedullary
hematopoiesis), and kidneys (RBC pooling).89
Literature review of gene therapy applications. The Bcl11a conditional erythroid
knockout mouse was also crossed with the Townes mouse showing similar effectivity and
phenotype correction compared to the Berkeley mouse97. In addition, the Townes model
was recently used to validate and support a β-globin gene addition strategy
(GLOBE/AS3).71 GLOBE/AS3 is a self-inactivating lentiviral vector that harbors a triplemutant form of β-globin (T87Q, G16D, and E22A) that prevents sickling and increases
affinity for α-globin.70 Together, this vector showed significant ability to improve
hematocrit, hemoglobin and RBC counts in recipient mice that received transduced
Townes HbSS mouse bone marrow cells.71
β-YAC
The β-YAC model was created by addition of a 240-kb yeast artificial
chromosome (YAC) onto a thalassemic background and crossed to α-globin knock-out
mice to result in a model of solely human globin expression.98,99 Variations of this model
are used with and without the sickle cell mutation to study hemoglobin regulation in
vivo.98–100

Effects of Gene Editing
While gene editing holds great promise for the future of genetic therapies, it is
important to understand the mechanism of editing and the potential negative effects that
could offset the desire outcome. Below is a detailed look at some of the deleterious
outcomes of DNA DSB-induced editing at both a DNA and cellular level.

DNA damage and double strand breaks
The cellular pathways that detect, signal, and repair all forms of DNA damage are
known as the DNA damage response.101 The repair pathways are critical in achieving a
desired gene editing outcome whether its random indels by NHEJ or a specific sequence
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inserted by HDR.56 CRISPR/Cas9 technology utilizes the endonuclease function to create
DSBs at a target cut site followed by p53 and Cdkn1 (p21) activation which aid the cell
by triggering cell cycle arrest and DNA repair.102–104 DSBs are considered the most
cytotoxic form of DNA damage and, if left unrepaired, DSBs can result in genome
instability or cell death (Figure 1-9).104
Immediately following a DSB, cell-cycle checkpoint proteins are activated and
the cell temporarily arrests.105 It is at this point that the cell works to repair the DSB,
leading to multiple possible outcomes. If the damage is manageable, the cell will likely
initiate repair by either NHEJ or HDR and return through the cell-cycle to continue
replication. If there are too many DSBs or the DNA damage is too great, the cell will
trigger apoptosis or undergo genomic changes that result in chromosomal abnormalities
and further instability.105

Chromosomal abnormalities
Chromosomal abnormalities (CAs) can result from heightened or unresolved
DNA damage. Some of the most notable CAs are: aneuploidy (abnormal chromosome
number), structural rearrangements (deletions, duplications, or insertions of a
chromosomal fragment), and chromosomal elimination.106 Micronuclei, abnormal nuclear
structures formed from missegregation of a portion (or entire) chromosome during cell
division, can also be attributed to DNA damage.107 While these structures form naturally,
increases in their frequency can be indicators of wider genomic instability. These
structures further add to CAs in that the replication that occurs within the micronucleus is
often out of sync with the primary nucleus leading to copy number changes.108

Off-target editing
Repetition and sequence similarity within every organism’s genome means that
off-target effects (OTE) can be a concern when editing homologous regions.
CRISPR/Cas9 (Streptococcus pyogenes) editing requires 17-20 base pairs of homology
between the target sequence and the gRNA as well as an appropriate 5’ PAM sequence
(NGG).109 gRNAs can tolerate up to 5 mismatches, continuing to guide the Cas9 to create
indels at off-target sites. Optimal gRNA design can minimize the likelihood of OTEs, but
high throughput methods are needed to identify regions of off-target cleavage. There are
multiple approaches to nominating potential off-target cleavage sites: computational, cellbased (DISCOVER-seq and GUIDE-seq), and in-vitro (CHANGE-seq and CIRCLEseq).109–114

Alternatives to traditional gene editing
To avoid the potentially negative effects resulting from DSB-induced gene
editing, groups have worked to make technological improvements that can prevent such
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Figure 1-9. Possible cellular outcomes after CRISPR/Cas9-induced DSBs.
During CRISPR/Cas9 gene editing, DSBs are created by the Cas9 endonuclease at the
gRNA target sequence. Each DSB activates p53 and p21 starting a cascade of effects
depending on the cell’s ability to repair the DSB. Modified with open access permission.
Conti, A., Di Micco, R. p53 activation: a checkpoint for precision genome editing?
Genome Med 10, 66 (2018). https://doi.org/10.1186/s13073-018-0578-6.104
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effects. Base editing uses a catalytically inactive Cas9 that is still directed by sequence
specificity but nicks the DNA rather than create DSBs, which allows for a tethered
enzyme to alter a specific base pair.115 In 2016, this technique was developed using a
cytidine deaminase to change a C to T and followed shortly by the evolution of the A to
G base-editor using an adenine deaminase.115,116
This strategy has important implications disease-associated SNPs. For SCD
specifically, both mutation correction and HbF induction approaches can be achieved
with base editing. Unfortunately, correction of the SCD mutation cannot be directly
corrected with the current base editing technologies. This obstacle can be overcome by
even newer editor technologies like “prime-editors”, or by a mutation “replacement”
strategy such as the use of base editing to convert the SCD mutation to the benign Hb GMakassar variant.35,36,117
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CHAPTER 2.

METHODOLOGY

Mouse Bone Marrow Isolation and Culture

Mice
Berkeley (Jackson Labs #003342) and Townes (Jackson Labs #013071) SCD
mice were obtained from Jackson Labs, and colonies were maintained in house according
to IACUC protocols. Breeding strategies were performed as suggested by Jackson Labs
(homozygous sickle males with heterozygous females) for both models to improve
success of pregnancy. Genotyping was performed by separated PCR, primer pairs are
shown in Table 2-1. Recipient mice used for transplantations were PepBoy mice
(CD45.1, Jackson Labs, Stock# 002014) or C57Bl/6 (CD45.2, Jackson Labs, Stock#
00662). For transplantation, recipients were lethally irradiated (1125 cGy) up to 24 hours
prior. Cells in PBS were injected via tail vein (200uL volume). After injection, mice were
given antibiotic water (Baytril) and given access to mush food. For survival studies,
animals were watched for signs of lethargy or illness and placed on heating pad while
critically analyzed by veterinarians according to IACUC protocols.
Bone marrow isolation, lineage negative (Lin-) cell purification and culture
Bone marrow was isolated from two femurs, tibias, hip bones and humeri by
flushing with Iscove's Modified Dulbecco's Medium (IMDM, Gibco #12440053) with
10% FBS. Whole bone marrow was lysed with ACK Lysing Buffer (Quality Biological
Cat#118156101) and filtered through a 40µm cell strainer. Lin- cells were obtained by
MACs column negative selection after staining with a lineage cocktail (CD5, CD45R
(B220), CD11b, Anti-Gr-1 (Ly6G/C), 7-4, and Ter-119) (Miltenyi Cat#130-090-858).
Lin- cells were cultured in StemSpan Serum Free Expansion Medium for hematopoietic
cells (SFEM, StemCell Technologies, #09650) with a cytokine cocktail (mIL3, mIL11,
FLT3 ligand, and mSCF) and PenStrep. Lin- cells were prestimulated for 24 hours in a
cytokine-enriched SFEM (above) media before electroporation by RNP (see below).
Cells were counted in PBS (10% Trypan Blue) using the Countess II (Invitrogen).
Lin- cell electroporation
RNP complexes were formed by incubating gRNA and Cas9 (Berkeley
Microlabs) in ddH20 and electroporation buffer (10 mM HEPES, 150 mM NaCl) for 30
minutes at room temperature. Lin- cells were electroporated with RNPs using the Neon
Transfection System (ThermoFisher Scientific MPK5000) and optimization program #5
(pulse voltage: 1700, width: 20, and pulse no.: 1). Cells and RNPs were mixed in Neon
Buffer T in 100uL tips and Buffer E2. (ROSA26: ACTCCAGTCTTTCTAGAAGA,
HBG: CTTGTCAAGGCTATTGGTCA, Makassar:
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Table 2-1.

Primer sequences used for each animal model and their appropriate applications.

Gene or Locus

Species

Hbb-b1.F
Hbb-b1.R
HBB.F
HBB.R
11127

Primer Sequence 5’ to 3’

Model

Application

Mouse

Berkeley

Genotyping

Human

Berkeley

Genotyping

Mouse

Townes

Genotyping

AAAGGTGAACTCCGATGAAGTTGG
ATAGGAAGGTTGAGCAGAATAGCC
ACATTTGCTTCTGACACAACTGTG
ACCACCAGCAGCCTAAGG
TTGAGCAATGTGGACAGAGAAGG

11128

Human

Townes

Genotyping

GTTTAGCCAGGGACCGTTTCAG

320

11129

Human

Townes

Genotyping

AATTCTGGCTTATCGGAGGCAAG

250

11798

Mouse

Townes

Genotyping

ATGTCAGAAGCAAATGTGAGGAGCA

432

MinION.F

Human

Townes

MinION seq

TTTGGCTCCAGGCACATTCCCACATCAAGATAAAGAGAAAC

≈18.5kb
mWT

284
n/a

AGTGGGTTGCATGGGTTCCTTACACACTTTGCA

MinION.R
HBA1.1.F
HBA1.1.R
HBA1.2.F
HBA1.2.R
HBBandHBG.1.F
HBBandHBG.1.R
HBBandHBG.2.F
HBBandHBG.2.R
MiniLCR.1.F
MiniLCR.1.R

Product
Size (bp)
442

Human

Berkeley

TLA seq

Human

Berkeley

TLA seq

Human

Berkeley

TLA seq

Human

Berkeley

TLA seq

Human

Berkeley

TLA seq

GCTCTGCCCAGGTTAAGG
GTTGGTCTTGTCGGCAGG
CCAAATACCGTTAAGCTGGA
CTTGAAGTTGACCGGGTC
TATCAGAATGGCCCTAGTCT
ACTTCCGCAGAACACTTTAT
TTGTCTAAGTTGCCTCGAGA
CGTCTTCAGCCTACAACATAC
CTCAGCCACCCTAATAGC
GGACAGAGCACATTATAATTAAC
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242
265
751
575
75

Table 2-1.

(Continued).

Gene or Locus

Species

Model

MiniLCR.2.F
MiniLCR.2.R
HBGprom.DS.F
HBGprom.DS.R
mROSA26.DS.F
mROSA26.DS.R
hHBB_Mak.DS.F
hHBB_Mak.DS.R
Mcdkn1.F
Mcdkn1.R
GAPDH.F
GAPDH.R

Human

Berkeley

TLA seq

Human

Both

NGS

Mouse

Both

NGS

Human

Both

NGS

Mouse

Both

qPCR

Mouse

Both

qPCR

Primer Sequence 5’ to 3’

Application

TGTCTATATGGGTCGTTGTG
AAAGACAAGCACGTGGAC
ACTGAATCGGAACAAGGCAAAGGCT
ACCCATGGCGTCTGGACTAGGAGCT
TTCTGGGAGTTCTCTGCTGC
TGGAAAATACTCCGAGGCGG
TGGCCAATCTACTCCCAGGAGCAGG
TCAAAGAACCTCTGGGTCCAAGGGT
AGCCTGACAGATTTCTATCACTCC
TGGGCACTTCAGGGTTTTCT
GTGTTCCTACCCCCAATGTG
AGGAGACAACCTGGTCCTCA
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Product
Size (bp)
130
268
344
390
n/a
n/a

TTCTCCACAGGAGTCAGGTGNR). For transplantations, cells were allowed to
recover overnight before injection.

Transplantation analyses
Mice were followed for 18 weeks post-transplantation and analyzed at 6, 10, 14
and 18 weeks for maintenance of indels, engraftment, HbF induction (F-cells and %
HbF), and complete blood count values. Peripheral blood was collected retro-orbitally
using heparinized micro-hematocrit capillary tubes (Fisher Scientific, Cat# 22-362-566).
Complete blood counts were determined on a FORCYTE Veterinary Hematology
Analyzer. Blood smears were performed using modified Romanowsky methanolic
staining and eosin and thiazin methods.118 Histology of organ cross sections was
performed using normal histological methods.

Functional Assays

Flow cytometry
Lin- cells in culture were incubated with BrdU for 1 hour before flow preparation
following FITC BrdU Flow Kit (BD Pharmingen, Cat# 559619). For apoptosis studies,
Lin- cells in culture were prepared using the FITC Annexin V Apoptosis Kit (BD
Biosciences, Cat# 556547). For F-cell quantification, 1uL of peripheral blood was fixed
with 0.05% glutaraldehyde and permeabilized with 0.1% TritonX-100 before staining
with anti-HbF-APC (Clone HBF-1, Invitrogen, Cat# MHFH05). F-cells are identified as
cells staining positive for HbF. For engraftment determination, 5-10uL of peripheral
blood were lysed by 2-3 rounds of incubation in RBC lysis buffer. Resulting cells were
washed with PBS (1% BSA) and stained with CD45.1-PE (Clone A20, BD Pharmingen,
Cat# 553776) and CD45.2-FITC (Clone 104, BD Pharmingen, Cat# 561874). For
reticulocyte percentage, 1uL of peripheral blood was stained with Retic-COUNT (BD
Biosciences, Cat# 349204).

Q-PCR
RNA from 0.2 million cells was extracted with RNeasy Plus Mini Kit (Invitrogen,
Cat# 74134), and reverse transcribed using iScript cDNA Synthesis Kit (Bio-Rad, Cat#
1708890). Cdkn1 expression was quantified by SYBR Green qPCR (Power SYBR Green
PCR Master Mix, ThermoFisher Scientific, Cat# 4368577) using the QuantStudio 6 RealTime PCR System (ThermoFisher Scientific). Reactions were run using primers in Table
2-1 and normalized to GAPDH.
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High performance liquid chromatography
Hemoglobin separation was determined by HPLC. Ion-exchange HPLC was
performed using a Prominence HPLC System (Shimadzu Corporation) on peripheral
blood lysate from transplanted mice (Hemolysate Reagent: 0.005M EDTA, 0.07% KCN;
Helena Laboratories, Cat# 5125). Proteins were quantified by light absorbance at 220nm,
280nm, and 418nm using a diode array detector. % HbF was determined as area of the
HbF peak/ sum of the area of all tetramer peaks.

Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) and Spectral Karyotyping (SKY)
analysis were performed by the SJCRH Cytogenetics core facility. Lin- cells were
incubated with colcemid for four hours prior to harvesting by routine cytogenetic
methods. For FISH analysis, bacterial artificial chromosome (BAC) clones were
purchased from BACPAC Resources (bacpacresources.org, Children’s Hospital Oakland
Research Institute) and used as probes in signal segregation studies (Table 2-2), labeled
with either red-dUTP (AF594, Molecular Probes) or green-dUTP (AF488, Molecular
Probes). The appropriate pair of labeled probes were combined with sheared mouse DNA
and hybridized to interphase and metaphase cells in a solution containing 50%
formamide, 10% dextran sulfate, and 2X SSC. Cells were stained with 4,6-diamidino-2phenylindole (DAPI) and analyzed. For most samples 50 Interphase nuclei were scored
for the presence of micronuclei and segregation of probe signal. For SKY analysis, a
commercially prepared SKY probe (Applied Spectral Imaging, Carlsbad, CA) was used
and Applied Spectral Imaging protocols were followed for the hybridization and
detection steps. 50 Metaphase cells were analyzed for chromosome loss and
fragmentation.

Genomic Sequencing Technology

Target locus amplification
Target Locus Amplication (TLA) sequencing was performed on Berkeley Hbb-/splenocytes (Cergentis). Splenocytes were obtained by crushing the spleen through a
40µm cell strainer and performing a subsequent RBC lysis. Lysed splenocytes were
washed with PBS (10% FBS) and frozen down at 10e7 per vial in freezing media (PBS
+10% DMSO, 10% FBS). Cells were cross-linked and ligated per the published
protocol.119 PCR pairs (Table 2-1)were designed to each of the transgenic fragments
within the Berkeley mouse.
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Table 2-2.

Cytogenetics BAC probe information.

BAC Probe Name
RP23-308J23
RP24-347O20
RP23-25C20
RP23-367M2
RP23-239C8
RP23-33G8

Species
Mouse
Mouse
Mouse
Mouse
Mouse
Mouse

Location
Centromeric to 1A5
Telomeric to 1A5
Centromeric to 7E5
Telomeric to 7E5
Centromeric to 6E3
Telomeric to 6E3
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Coordinates
Chr1:26,106,021-26,275,300
Chr1:26,305,166-26,440,332
Chr7:103,573,095-103,768,675
Chr7:103,894,127-104,083,626
Chr6:112,778,187-113,016,809
Chr6:113,106,213-113,297,830

Next-generation sequencing
Targeted amplicons were generated using gene specific primers (Table 2-1) with
partial Illumina adapter overhangs and sequenced as previously described.120 DNA was
obtained either by lysing cell pellets of less than 0.1 million cells or using DNeasy Blood
& Tissue Kit (Qiagen, Cat# 69504), and used to generate gene specific amplicons with
partial Illumina adapters in PCR#1. Amplicons were indexed in PCR#2 and pooled with
other targeted amplicons for other loci to create sequence diversity. Additionally, 10%
PhiX Sequencing Control V3 (Illumina) was added to the pooled amplicon library prior
to running the sample on an Miseq Sequencer System (Illumina) to generate paired 2 X
250bp reads. Samples were demultiplexed using the index sequences, fastq files were
generated, and next generation sequencing (NGS) analysis was performed using CRIS.121

Fragment amplification and Oxford Nanopore MinION sequencing
Oxford Nanopore Technologies MinION sequencing was performed on an
approx. 12-14kb fragment amplified from Townes HbSS mouse DNA extracted from
peripheral blood. The fragment was amplified using PrimeSTAR GXL DNA Polymerase
(Takara Bio, Cat# R050A) and purified using QIAQuick Gel Extraction kit (Qiagen, Cat#
28704).The library was prepared using the Ligation Sequencing Kit (Oxford Nanopore
Technologies, Cat# SQK-LSK109) per the published 1D Genomic DNA protocol. The
library was loaded onto a MinION flow cell (R9.4.1, Oxford Nanopore Technologies,
Cat# FLO-MIN106D) and sequenced on the MinION device for 1 hour. Reads were
identified using MinKnow software.
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CHAPTER 3.

GENOMIC CHARACTERIZATION OF SCD MOUSE MODELS

Genomic Characterization of SCD Mouse Models
In order to test gene editing strategies within a mouse model, sequence specificity
of the target region and any regulatory regions is needed. Mouse models created prior to
technological advancement in sequencing technology may lack sequence specific
information. For example, the integration site and copy number of the human globin
sequence within the transgenic Berkeley mouse model of SCD remains unknown. To
address this gap in knowledge and better understand the limitations of this model for gene
editing purposes, we performed next-generation sequencing.

Integration and copy number estimation of the Berkeley mouse transgene
Target Locus Amplification (TLA) sequencing was performed on splenocytes
from homozygous (Hbb-/-) Berkeley mice122. This technique uses PCR primer sets to
sequence the breakpoints of the transgenic fragments of interest in circularized segments
of DNA that are within proximity to each other. In this experiment, the three human
transgenic fragments (HBA1, mini-LCR, and 39kb of HBG1 to HBBS) were used as
targets, each with two primer sets—one at the 5’ and one at the 3’ end of the sequence.
All reads were mapped against both the human and mouse genomes to determine
orientation and integration site, respectively. Fusion reads that spanned the human
transgenic fragments and the mouse genome identified the transgene integration site
(TIS) to be mchr1: 26,274,199-26,274,861, mm10 (Figure 3-1A). Fluorescence in situ
hybridization (FISH) using a mchr1 and HBB probe confirmed the approximate location
of the TIS (Figure 3-1B).
To determine the copy number of transgenic fragments within the Berkeley
mouse genome, sequence coverage and fusion reads were critically analyzed. Human
genome coverage was orders of magnitude greater than the mouse genome which led to
an estimate of >10 copies of the human transgene (Figure 3-1C). To further support this
finding, every possible combination of fusion read was recorded including those that
indicated repeated, head-to-tail concatemers. We sought further evidence to validate this
high copy number and turned to FISH analysis using probes flanking the newly identified
TIS. The two probes, 30kb apart in the wildtype mouse genome, were shown to have a
large distance between them in the transgene-containing allele of heterozygous Berkeley
fibroblasts (Figure 3-1D). This further supports the presence of a large transgenic
fragment of >500kb integrated between the probes.
In an attempt to further clarify the orientation of the multiple transgenic
fragments, we performed PacBio long-read sequencing using 97 probes spanning the
extended human β-globin locus. This technique provided further confirmation of the
insertion site and estimated high copy number; however, the orientation and an exact
copy number remained undetermined (Figure 3-2). Together these data provide ample
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Figure 3-1. Configuration of the human globin transgenes in the Berkeley mouse
model for sickle cell disease (SCD).
(A) Target locus amplification (TLA) sequence showing human genome coverage across
the Berkeley mouse genome. The red box outlines the transgene integration site (TIS) in
human chromosome 1 zoomed in to show mouse genome coverage across the region. The
human TIS is indicated. (B) Metaphase fluorescence in situ hybridization (FISH) analysis
for human ß-globin (HBB, red) and an adjacent mouse chromosome (mchr) 1-specific
region (green). (C) Details of the transgene integration site. The human transgenic
sequence cassettes are shown below. Fusion reads and coverage plot of human ß-like
globin sequences across the region. (D) FISH analysis at TIS showing human transgene
(TG) and flanking probes located centromeric red) and telomeric (green) to the
integration site. Probes are 30kb apart in a wildtype mouse. Black dot indicates
centromere. Fibroblasts from mice heterozygous for the Berkeley transgene analyzed by
FISH using probes in panel E. The wild type (WT) and transgene (TG) alleles are shown.
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Figure 3-2. PacBio probe design and sequence coverage.
(A) Location of 97 PacBio probes across the extended β-globin locus. (B) PacBio reads
coverage confirming integration site of TIS. Additional peak was verified as a readmapping issue by FISH probing for transgenic sequences at ChrX.
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evidence of a mchr1 integration of multiple human globin fragments and can better
educate hypotheses for gene editing targets within the Berkeley model.

Sequence determination of human globin knock-in within Townes SCD mouse
The Townes model of SCD harbors portions of the human α and β-globin loci.
While the seminal literature on this mouse model includes information on the knock-in,
detailed breakpoints between the regions of mouse and human fusion remain to be
determined. Again, this information becomes more important as sequence specificity for
CRISPR/Cas9 gRNA targeting and the reliance of certain regulatory elements is needed.
The widely used Townes mouse contains the HBBS and HBG1 genes knocked into
the endogenous mouse β-globin locus; the published information is included (Figure
3-3A, Appendix). To determined breakpoint information, we performed Oxford
Nanopore MinION sequencing on a polymerase chain reaction (PCR) fragment amplified
from Townes HbSS DNA. The fragment obtained was approximately 12-14kb in size and
designed to encompass all of the β-globin locus knock-in including the mouse and human
breakpoints (Figure 3-3B). MinION sequencing yielded 47,020 reads and 226,170,000
estimated bases. The reads were compiled into a consensus sequence of 13,738 bp that
spanned the entirety of the knock-in and when aligned to the mouse and human genomes,
confirmed the published literature, and provided novel sequence-specificity (Figure 33C).
To better understand the impact of this genetic knock-in on regulation of the
globin genes, we mapped previously determined human and mouse open chromatin
(ATAC-seq) and erythroid transcription factors (BCL11A and GATA1) against the
Townes consensus sequence (Figure 3-3C). Furthermore, we looked at synteny between
the mouse and human β-globin loci to further touch on sequence conservation that may
serve a functional role in regulation of the Townes human globin knock-in (Figure 3-4).
Together, these findings elaborate on the previously published literature to provide
sequence specificity to benefit a gene editing audience. In addition, we provide a closer
perspective into the sequences that are missing from the Townes model

DNA Damage after Editing a Repetitive Transgene
After the determination of a complex and repetitive human transgene in the
Berkeley SCD mouse, we hypothesized that CRISPR/Cas9 editing within the transgene
may result in serious negative side-effects that outweigh any improvement brought by our
gene editing strategy. More specifically, we hypothesized that the damage done to HSCs
would prevent their successful engraftment or the production of any edited cells in
periphery. This hypothesis was based on the knowledge that DSBs are the most cytotoxic
form of DNA damage, and previously published literature demonstrating the DNA
damage associated with DSBs in repetitive elements.123
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Figure 3-3. Genomic structure of the Townes mouse model for SCD.
(A) Replacement of mouse -globin genes Hbb-bsmaj and Hbb-btmin with human -like
globin genes HBBS and HBG1 by homologous recombination, as described by Wu et al,
2006. The human and mouse -like globin loci are shown in the top two diagrams. The
modified locus in the Townes mouse is shown at the bottom. The PCR primers used to
amplify an approximately 13 kb fragment for long range sequencing are shown as black
arrows. (B) Agarose gel electrophoresis showing the amplicon generated by PCR of
Townes mouse DNA using the primer pair shown in panel A. The estimated size is
approximately 13 kb. (C) Configuration of the knockin locus based on long range
sequencing. Browser tracks show ATAC-seq and BCL11A occupancy determined by cutand-run.
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Figure 3-4. Synteny plot of the human (top) and mouse (bottom) β-globin locus.
Synteny is indicated by homology (red) and inverse homology (blue). Regions of white
indicate no homology between the two genomes.
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Increase in apoptosis and cell cycle arrest after transgene editing
To assess the DNA damage after editing within the HBG promoter in the
Berkeley transgene, we electroporated mouse Lin- cells with RNPs and cultured for five
days while taking intermittent measurements of apoptosis and cell cycle (Figure 3-5).
The controls used were electroporations of Cas9 protein only (Cas9) and Rosa26 gRNA
(Rosa26) RNPs designed as a non-transgene editing control (Figure 3-5B). Efficient
editing was achieved in Berkeley Lin- cells edited at the HBG promoter (n=4, 77.6 ±
1.6%) and Rosa26 locus (n=4, 94.2 ± 0.9%) 72 hours post-electroporation and remained
stable for the remainder of the culture period (Figure 3-5C). Cell counts showed a
significant reduction in growth by 120 hours post-electroporation when edited at the HBG
promoter in Berkeley Lin- cells (3.6E5 ± 1.2E5 cells) compared to Rosa26 controls
(8.2E5 ± 9.0E4 cells, p=0.0002) (Figure 3-5D). An initial increase in cells undergoing
apoptosis, as determined by Annexin V positivity by flow cytometry, was seen in HBG
promoter edited Berkeley Lin- cells (59.1% ± 2.6% at 48 hours) was observed over
Rosa26 (30.5% ± 2.6%, p=0.0002) (Figure 3-5E). Cell cycle analysis by BrdU uptake
indicated a significant dropout of cells from S phase when edited within the Berkeley
transgene (16.3% ± 2.8% at 48 hours) compared to Rosa26 (33.0% ± 2.9%, p=0.0004)
and normalized concurrently with apoptosis (Figure 3-5F). Editing within the Berkeley
transgene caused a spike in Cdkn1 (p21) expression (4.0 ± 0.9 fold change at 8 hours), an
indicator of p53 activity, over Rosa26 (2.4 ± 1.0 fold change, p=0.0388) (Figure 3-5G).
Efficient editing of the same target site in Townes Lin- cells did not result in
increased apoptosis or cell cycle stall, as well as no effect on cell growth compared to
controls (Figure 3-6A-E). In addition, we confirmed this toxicity was not gRNA or
manufacturer dependent by testing the same gRNA from two different manufacturers
demonstrating equivalent effects on DNA damage (Figure 3-7). These results show a
heightened and prolonged period of DNA damage response after editing within the
transgene over external non-transgene controls due to more DSB-induced editing.

Increase in chromosomal abnormalities after transgene editing
Given the sensitivity of editing a stem-cell population we sought to determine if
an increase in DNA damage in the Berkeley model would result in an increase in
chromosomal abnormalities (CAs). Associations between CAs and DSBs have been
shown in various cell types.124,125 To quantify CAs after editing, we designed a
cytogenetic assay using two FISH probes flanking the gRNA cut site(s). Segregation of
the two signals (red and green, overlapping in normal context) indicates abnormalities,
and in some instances can be categorized accordingly (ie. copy number gain/loss,
elimination). In addition, the presence of micronuclei can be determined and attributed to
DNA damage.
Fifty interphase Berkeley Lin- cells were screened for segregation of centromeric
and telomeric probes flanking each site of editing and micronuclei 24 and 120 hours
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Figure 3-5. Heightened DNA damage response following Cas9 editing of the
human HBG promoter hematopoietic stem and progenitor cells (HSPCs) of
Berkeley transgenic mice.
(A) Experimental strategy. Lineage-negative (Lin-) bone marrow cells were
electroporated with a ribonucleoprotein (RNP) complex consisting of Cas9 + single guide
(sg) RNA against the BCL11A binding site in the HBG promoter, or against intron 1 of
the Rosa26 locus (see panel B), cultured for five days in medium (with mSCF, hFLT3
ligand, mIL-3 and mIL-11) designed to expand HSPCs and analyzed serially. (B) sgRNA
sequences (underlined) corresponding to targeted regions indicated by red bars in the
HBG promoter and Rosa26 intron 1. The sgRNA PAM sequence is indicated by red text.
(C) The percentages of insertion-deletion (indel) mutations in genomic DNA, determined
by next generation sequencing (NGS) of PCR products generated across the targeted
region. Controls include electroporation with Cas9 alone or unelectroporated cells (Ctrl).
(D) Live cell numbers counted by hemocytometer using trypan blue exclusion. (E)
Percentages of apoptotic (AnnexinV+) cells measured by flow cytometry. (F) Percentages
of S-phase cells measured by incorporation of BrdU after a 60 minute incubation
followed by flow cytometry. (G) Fold-change in Cdkn1 (p21) mRNA measured by realtime quantitative PCR (RT-qPCR), normalized to mouse Gapdh mRNA. All graphs show
data as mean ± SEM of data generated 2 biological replicate experiments., each with
technical replicates ***p<0.001 by Two-way ANOVA for HBG versus Rosa26 edited
cells.
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Figure 3-6. Normal DNA damage response after Cas9 editing of the human HBG
promoter in Townes SCD mice.
Bone marrow-derived Lin- HSPCs were edited by electroporation of RNP and analyzed
serially, as described for Berkeley mice in main Figure 3. (A) Percentages of on-target
editing versus time. (B) Cell number versus time. (C) Percentages of apoptotic cells
determined by Annexin V immuno-flow cytometry. (D) Percentages of S-phase cells
measured by BrdU incorporation. (E) Fold change in Cdkn1 gene expression measured
by RT-qPCR, normalized to mouse Gapdh. Panels show data as mean ± SEM of 2
independent experiments, n=4 per condition. ***p<0.001 by Two-way ANOVA for HBG
and Rosa26 datasets.
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Figure 3-7. Testing HBG promoter gRNA from two companies to rule out
manufacturers and preparation as a variable in toxicity.
(A) Cell number versus time. (B) Percentages of on-target editing versus time. (C)
Percentages of apoptotic cells determined by Annexin V immuno-flow cytometry.

38

after electroporation. These selected timepoints allowed for a comparison of large-scale
chromosomal changes during acute DNA damage and after a period of recovery. Probe
locations for CA determination by FISH after editing the HBG promoter (mchr1) in
Berkeley Lin- cells are shown (Figure 3-8A). Micronuclei were detected and quantified
accordingly (Figure 3-8B). The frequency of cells with chromosomal abnormalities (as
determined by any change in a normal diploid, 2 red/green probe pair combination) were
quantified for HBG editing (Figure 3-8C). After 5-days, micronuclei continued to persist
but at a lower frequency, while most CAs were resolved or eliminated. Examples of the
presence of micronuclei, signal segregation within nucleus and/or micronuclei, and copy
number alterations can be seen (Figure 3-8D). Similarly, Rosa26 editing was analyzed
for micronuclei frequency and CAs. A separate set of probes were designed to flank the
Rosa26 editing site on mchr6 (Figure 3-8E). While micronuclei formation was roughly
equivalent in between the Rosa26 (Figure 3-8F) and HBG promoter, the presence of CAs
was significantly lower when editing the Rosa26 locus (Figure 3-8G).
Townes Lin- cells were similarly tested for micronuclei formation and CAs. Using
a similar probe design that flanked the mouse β-globin locus (location of human β-globin
knock-in) (Figure 3-9A). There was no difference in the average percent of cells
containing a micronucleus when edited at the HBG promoter or with Cas9 only, and very
few HBG edited cells had abnormalities (Figure 3-9B, C). While testing the Rosa26
edited controls in the Townes Lin- cells, micronuclei were again not significantly
increased over Cas9 controls although there were a few abnormalities present at 24 hours
(Figure 3-9D-F). This demonstrates a background level of micronuclei that will be
induced after editing with RNPs regardless of the locus.
Next, we tested an edited and unedited population of Berkeley Lin- cells for
translocations and chromosomal abnormalities as measured by spectral karyotyping
(SKY). SKY analysis performed on 50 metaphase cells for chromosome loss, structural
and breakage alterations (Figure 3-10)) showed a similar frequency of abnormalities
(52%). Various forms of chromosomal deletions and breakages, as well as fragmentation
can be seen. Importantly, no translocations were identified.

HSC engraftment is affected by transgene editing
Next, we sought to determine the effect of increased DNA damage and CAs
resulting from multiple DSBs within the transgene of Berkeley model on HSCs and their
ability to engraft. To test this, Berkeley Lin- cells were edited at the HBG promoter and
Rosa26 locus and injected into lethally irradiated C57Bl/6 PepBoy mice after overnight
recovery (Figure 3-11A). After 18 weeks post-transplant, overall survival of HBG
promoter edited Berkeley cell recipients was significantly lower than Cas9 control mice
(p=0.0011) (Figure 3-11B). Additionally, in surviving HBG promoter edited Berkeley
Lin- recipient mice, engraftment was significantly less efficient than that of Rosa26edited (p<0.0001) or Cas9 control mice (p<0.0001) at 6 weeks post-transplant (Figure 311C) supporting the hypothesis that transgene editing would negatively affect the
engraftment potential. During the course of the transplantation, engraftment of HBG
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Figure 3-8. Chromosome instability after editing the globin transgene of Berkeley
mice.
(A) Probe location for Berkeley transgene CA FISH determination in Berkeley
metaphase cells. (B) Micronuclei and (C) CA frequency. (D) Representative images of
micronuclei and CAs. (E) Probe location for Rosa26 CA FISH determination in Berkeley
metaphase cells. (F) Micronuclei and (G) CA frequency. Frequency is measured as
percent of total metaphase cells (50) per sample, each dot represents an individual
sample/electroporation.
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Figure 3-9. Micronuclei or chromosomal abnormalities are not induced by
genome editing of the HBG or Rosa26 locus in the Townes mouse.
(A) Probe location for Townes knock-in CA FISH determination in Townes metaphase
cells. (B) Micronuclei and (C) CA frequency. (D) Probe location for Rosa26 CA FISH
determination in Townes metaphase cells (same as Figure 3-8E, endogenous Rosa26
locus). (F) Micronuclei and (G) CA frequency. Frequency is measured as percent of total
metaphase cells (50) per sample, each dot represents an individual
sample/electroporation.
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Figure 3-10. SKY analysis of 50 HBG promoter edited metaphase Lin- cells.
Classification of chromosomal abnormalities determined by spectral karyotyping (SKY)
of individual cells (percent of total cells, n=50 evaluated). Panels a-f show representative
mchr1 SKY images corresponding to abnormalities noted in the pie chart above. For
each panel, the chromosome image is shown in gray and the pseudocolor image after
pixel classification is shown on the right; yellow indicates a mchr1 origin. Images show
fragments, deletions, or chromosome breaks
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Figure 3-11. Transgene-edited Berkeley mouse HSPCs fail to engraft.
(A) Experimental strategy. (B) Kaplan-Meier curves showing survival of irradiated
recipients after transplantation of edited HSPCs. (C) Engraftment of HSPCs, as
determined by the fraction of donor (CD45.2+) blood mononuclear cells. (D) On-target
indels at HBG or Rosa26 in blood mononuclear cells. Graphs show mean ± SEM of 2
biological replicate experiments with n= 13 HBG. 9 Rosa26, and 10 Cas9 mice.
***p<0.001 by t-test.
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promoter edited recipients greatly improved but corresponded to decrease in editing
(<5% indels) in peripheral blood (Figure 3-11D). This result further proves that editing
HSCs within the Berkeley transgene is incompatible with successful engraftment. These
results showed that the heightened DNA damage response after creating multiple DSBs
within the Berkeley transgene was enough to prevent engraftment of edited HSCs,
provided sufficient evidence that the Berkeley mouse model is insufficient to test
preclinical CRISPR/Cas9 editing strategies.

Editing Known HBG Repressor in Townes Mouse
As a comparison to the Berkeley mouse, Townes Lin- cells were tested in each
measurement of DNA damage and HSC engraftment potential. In the previous sections,
we showed little to no apoptosis or CA frequency above background in the Townes
model. This led to further tests of the Townes’s model’s ability to induce HbF
therapeutically and correct SCD phenotype.

Slight induction of HbF after editing at the HBG promoter in the Townes mouse
To test HbF inductions and phenotype correction, Townes HbSS Lin- cells were
edited at the HBG promoter and infused into lethally irradiated C57Bl/6 recipients. As
with the Berkeley model, efficient editing was achieved after HBG promoter editing (57.1
± 3.1% indels) and maintained throughout the transplant (Figure 3-12A). Transplantations of edited Townes Lin- cells had no effect on survival (Figure 3-12B) or engraftment
(Figure 3-12C). Our previously published work in human CD34+ cells would suggest
that indels of 50-60% in the HBG promoter would be sufficient for HbF induction of
approximately 30%.78
This motivated us to determine the extent of HbF induction within recipients of
HBG promoter edited Townes Lin- cells. HbF induction was measured by flow cytometry
(HbF+ or F-cells) and HbF protein by ion exchange-high performance liquid
chromatography (IE-HPLC). F-cells were increased from 2.9% ± 0.2% in Cas9 mice
compared to 16.0% ± 2.5% in the HBG promoter edited Townes Lin- recipient mice
(p=0.0002; Figure 3-12D)). HbF protein increased to 3.5% ± 0.4% in edited mice over
Cas9 mice (0.2% ± 0.1%, p<0.0001) by 18 weeks post-infusion (Figure 3-12E).

SCD phenotype is unaffected by low levels of HbF induction
To determine if the corresponding increase in HbF was enough to alleviate the
sickle cell phenotype within the Townes Lin- cell recipient mice, reticulocyte analysis by
flow cytometry and complete blood counts (CBCs) were performed during the transplant.
Reticulocyte levels were not significantly higher in Cas9 mice over the course of the
transplant (Figure 3-12F). Additional values such as hemoglobin levels (Figure 3-12G)
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Figure 3-12. Townes mouse HSPCs edited at the HBG promoter engraft efficiently
but fail to recapitulate human hereditary persistence of fetal hemoglobin.
(A) Kaplan-Meier curves showing survival of recipients after transplantation of edited
HSPCs. (B) Engraftment HSPCs, as determined by the fraction of donor (CD45.2+) blood
mononuclear cells. (C) On-target indels at the HBG promoter in blood mononuclear cells.
(D) HbF immunostaining cells (“F-cells) determined by flow cytometry. (E) HbF protein
fraction in red blood cell lysates, as determined by ion-exchange high performance liquid
chromatography. (F) Percentage of reticulocytes. (G) Blood hemoglobin levels (g/dL).
(H) Total red blood count in peripheral blood. (I) Spleen weight. Graphs show data as
mean ± SEM of 3 independent transplants, n=13 HBG promoter and n=9 Cas9 Townes
Lin- recipient mice. ***p<0.001 by t-test.
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and red blood cell counts (Figure 3-12H) were not significantly improved by editing at
the HBG promoter. In addition, spleen weight was not decreased by editing at the HBG
promoter in Townes Lin- cells recipients (Figure 3-12I). Our results show that despite
successful engraftment and a high frequency of indels in the HBG promoter following
genome editing of Townes Lin- cells, the HbF induction was not high enough to correct
the SCD phenotype. When compared with levels of HbF induction in human cells edited
at the same region, the Townes mouse HbF is ten-fold less than that of human, rendering
the lack of phenotype correction not surprising (Figure 3-3C). Our genomic
characterization of the Townes knock-in and a critical analysis of the sequences involved
can provide possible explanations for this result.
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CHAPTER 4.

IMPROVEMENT OF TOWNES MOUSE SCD PHENOTYPE BY
BASE EDITING THE SCD MUTATION*

As mentioned in Chapter 1, mutation correction by correcting the sickle cell
mutation is an ongoing strategy for gene-therapy. However, given the restraints of HDR
and lack of technology to alter the T(sickle) to an A(healthy) in HSCs, we sought an
alternative strategy. Altering the SCD mutation to the Hb G-Makassar mutation, a rare
but believed to be benign mutation, is an alternative strategy that may work to prevent
polymerization of hemoglobin molecules (Figure 4-1). This strategy can be
accomplished through the use of adenosine base editors (ABE), adenosine deaminase
enzymes tethered to an inactivated Cas9 mutant.116 ABEs use the Cas9 to nick the DNA,
and the allow the deaminase to alter an adenosine to an inosine which is read as a
guanosine by the polymerase.116 The Hb G-Makassar alanine is similarly hydrophobic,
though smaller in size, to the HbS Valine which is believed to play a major role in
preventing the polymerization of Hb G-Makassar β chains. Not only does this strategy
allow us to study the effects of a rare hemoglobin variant, but also allows us to test its
potential as a therapeutic strategy. This work was performed as a collaboration between
Dr. David Liu’s group at the Broad Institute and Dr. Mitchell Weiss’ group at St. Jude
Children’s Research Hospital as part of the St. Jude Collaborative Research Consortium.
Efficient Base Editing in Recipient Mice Transplanted with Townes Mouse LinCells
Recreation of the Hb G-Makassar mutation by ABEs performed Townes Lin- cells
in a similar method as stated in Chapter 3. Townes HbSS Lin- cells were prestimulated
18-24 hours after harvesting in Lin- negative media before electroporating with ABE
RNPs. Cells were then allowed to recover overnight in Lin- media prior to injection into
lethally irradiated Pepboy (C57Bl/6 CD45.1+) recipients (Figure 4-2A). Transplantations
progressed to 16 weeks while collecting and analyzing peripheral blood at various
timepoints over the course of the transplant. High levels of base editing was achieved
(<60%) and maintained at high levels throughout the life of the transplant, alongside
engraftment levels of >90%. (Figure 4-2B, C). By hemoglobin electrophoresis and ion
exchange-HPLC, Hb G-Makassar and HbS are indistinguishable. We utilized a reversephase HPLC program optimized for separation of β-globin variants to show separation of
Makassar (βG) and Sickle (βS) globin chains. βG was induced to 80% of all β-like globin
chains in peripheral blood hemolysate at 16 weeks post-transplantation (Figure 4-2D).
These results show highly efficient engraftment of base edited mouse HSPCs and the
variant’s ability to produce high levels of the mutated globin chains.
----------------------------*Modified from final submission with permission. Newby, G. A.*, Yen, J. S.*, Woodard,
K. J.*, Mayuranathan, T.* et al. Base editing of haematopoietic stem cells rescues sickle
cell disease in mice. Nature (2021) https://doi.org/10.1038/s41586-021-03609-w.
(*authors contributed equally).36
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Figure 4-1. Location of sickle cell mutation and gRNA design to recreate Hb GMakassar.
The SCD mutation is located at the sixth codon of the β-globin gene, resulting in an A to
T mutation (sense strand). The Hb G-Makassar mutation can be created from the sickle
mutation using A to G base-editors (anti-sense strand).
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Figure 4-2. Base editing to recreate Makassar mutation in Townes Lin- cells.
(A) Transplantation strategy. (B) Engraftment HSPCs, as determined by the fraction of
donor (CD45.2+) blood mononuclear cells. (C) On-target base editing to Hb G-Makassar
in peripheral blood. (D) HbG protein fraction in red blood cell lysates, as determined by
reverse-phase high performance liquid chromatography. (E) Blood hemoglobin levels
(g/dL). (F) Percentage of reticulocytes. (G) Blood smears from experimental and control
animals. (H) Representative images and quantification (I) of sickled RBCs under
hypoxia. (J) Spleen weight. Graphs show data as mean ± SD of 1 independent transplant,
n=3 ABE1, n=3 ABE2, n=6 control, and n=2 HbAS Townes Lin- recipient mice.
***p<0.001 by t-test.
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Hb G-Makassar Mutation Improves Townes HbSS CBCs and Splenomegaly
To address SCD phenotype improvement with efficient ßG production in recipient
mice, CBC values and reticulocyte percentage by flow cytometry were determined on
peripheral blood. Hemoglobin values were greatly increased, and reticulocyte percentage
greatly decreased in both treatment groups, compared to unedited SCD controls (Figure
4-2E, F). In addition to hemoglobin and reticulocytes, almost all CBC values were
improved in the Makassar edited conditions (Table 4-1). Visual inspection of the blood
smears supported the CBC improvement by a noticeable decrease in sickled cells and an
overall decrease in the heterogeneity of the cell shape and size (Figure 4-2G). One
complication of SCD mouse models, is the ability to visualize sickle cells in the
peripheral blood. While they can be seen on blood smears, they are often fewer than
would be expected either because of a normoxic environment or because they remain
lodged within the bone marrow and vasculature. To better quantify sickled cells in the
transplanted mice, we performed a hypoxia-induced sickling assay on whole peripheral
blood (Figure 4-2H, I). In unedited HbSS recipient mice over 80% of all peripheral
blood cells sickled under hypoxia compared to 25-30% in RBCs from mice with the
Makassar mutation. Upon completion of the transplantation, animals were sacrificed and
organ histology performed. Splenomegaly was greatly improved in Makassar edited
animals and histology showed a similar improvement (Figure 4-2J).
To determine the profile of allelic edits in edited recipient mouse bone marrow,
colony forming unit (CFU) assays were performed. Five hundred Lin- cells from three
mice from ABE.2 group (protein prep containing 10% glycerol) were plated in triplicate
and allowed to grow for 10 days. NGS analysis from the resulting CFU colonies
determined a mix of monoallelic and biallelic edited clones (Figure 4-3).

Secondary Transplantation Confirms Base Editing in Long-term HSCs
To confirm efficient base edits of long-term HSCs, whole bone marrow from the
previously mentioned primary recipients was injected into lethally irradiated secondary
recipients (Figure 4-4A). Additionally, bone marrow from one edited (39% Hb GMakassar) and one unedited recipient mouse was mixed at varying ratios to address how
incremental increases in base edits improve the SCD phenotype. At 16 weeks posttransplantation, engraftment of greater than 90% was determined by CD45.2 positivity
(Figure 4-4B). Hb G-Makassar base edits were measured by NGS and shown to decrease
incremental as expected with lower ratios of edited bone marrow (Figure 4-4C). G
protein was detected by reverse-phase HPLC and shown to increase to >80% (Figure 44D). With incremental increases in Hb G-Makassar edits and G protein, CBC values
improved a level comparable with HbAS (heterozygous, carrier and healthy phenotype)
and HbAA (healthy) controls (Figures 4-4 E-H). A nonlinear dose response was shown
in hemoglobin values, reticulocyte, RBC, and WBC counts such that 20% Hb GMakassar appeared to be sufficient to reach healthy levels. Together, the secondary
transplant data proves highly efficient base editing in LT-HSCs that surpasses the level
needed for a therapeutic effect.
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Table 4-1.
Complete blood count values for Townes HbSS base edited recipient
mice at 16 weeks post-transplantation.
Condition
Number of mice
analyzed
RBC x106/uL
Reticulocyte %
Hb (g/dL)
Hct (%)
MCV (fL)
MCH (pg)
MCHC (g/dL)
RDW (%)
WBC x 103/uL
Platelets (x103/uL)

HbSS
6

ABE.1
3

ABE.2
3

HbAS
2

6.52 ± 0.37
41.45 ± 5.69
8.67 ± 0.42
25.33 ± 1.27
38.87 ± 0.83
12.72 ± 1.74
33.98 ± 1.65
35.72 ± 1.07
39.67 ± 7.36
558.2 ± 95.4

9.86 ± 0.38
17.77 ± 3.25
10.57 ± 0.46
29.37 ± 0.72
29.80 ± 0.53
10.70 ± 0.82
36.00 ± 2.13
28.03 ± 2.31
28.68 ± 5.79
525.0 ± 98.8

10.87 ± 0.85
9.67 ± 4.96
10.97 ± 0.31
32.03 ± 3.74
29.43 ± 1.48
10.10 ± 0.56
34.43 ± 2.91
26.13 ± 1.11
26.72 ± 9.26
704.7 ± 118.7

10.74 ± 0.04
9.46 ± 5.44
10.80 ± 0.71
31.35 ± 0.35
29.15 ± 0.21
11.90 ± 1.98
35.20 ± 0.85
23.65 ± 1.06
26.49 ± 10.17
735.2 ± 178.9
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Figure 4-3. Allelic editing of Lin- cells from three Hb G-Makassar edited mice.
Fraction of colonies with biallelic (dark blue), monoallelic (light blue), and unedited
(gray) edits in CFUs plated from ABE.2 mice. Lin- cells were plated in methylcellulose
(StemCell Technologies, Methocult) and grown for ten days prior to collection (n=36
colonies per mouse), lysis and NGS.
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Figure 4-4. Secondary transplantation shows efficient base editing of LT-HSCs
and a dose response to Hb G-Makassar.
(A) A secondary transplantation was performed by mixing ratios of edited (39%) and
unedited primary recipient RBC lysed bone marrow. Two million cells of each ratio were
injected into 3 lethally irradiated recipients each and animals were kept for 16 weeks
prior to analysis. (B) Engraftment measured by CD45.1 positivity in PB. (C) Makassar
allele base editing percentage measured by NGS on DNA extracted from PB. (D)
Percentage of G over all -like proteins measured by RP-HPLC. (E-H) Hemoglobin,
reticulocyte count, red blood cell count, and white blood cell count vs. base editing
percentage. Pastel colors indicate the edited:unedited ratio, brown dotted lines are
HBBA/S(HbAS) heterozygous controls and black dotted lines are HBBA/A(HbAA) healthy
controls. One phase nonlinear curves are shown with R2 values.
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CHAPTER 5.

DISCUSSION

A Highly Repetitive Transgene Prevents Accurate Study of Gene Editing
Therapeutic Targets Within the Transgenic Sequence
Mouse models of SCD have been used for years without fully understanding the
precise human sequence integrated into each model.66,69,97 With the rise in target-specific
gene editing strategies to improve disease phenotypes, a full understanding of the genetic
structures of these models is essential, especially for efforts to enhance fetal hemoglobin
production by genome editing. In this study, we use advanced sequencing technologies to
characterize the genomic configuration of the Berkeley and Townes SCD mouse models.
One of the key findings in this dissertation is the highly repetitive human
transgene integrated into a region of heterochromatin at chr1 within the Berkeley mouse
model. Both integration site and copy number are crucial to the overall performance of
the transgene and its resulting phenotype. Transgene integration within a gene or
resulting in a deletion can lead to phenotypes unrelated to the transgene itself, therefore
confounding the model’s use in disease studies.126 Additionally, multiple copies of a
transgene (a common occurrence with DNA microinjection) can contribute to position
effect variegation (PEV), the abnormal gene expression caused by the movement of a
euchromatic gene into or near a region of heterochromatin.127–129 Indeed, the Berkeley
globin transgene remains functionally active with an appropriate phenotype but our
strategy to perform genome editing within the transgene furthered the need for more
exact information on the transgene integration site.
Upon investigation, we found that the human transgene integrated into a gene
poor area. Therefore, it is unlikely that the transgene would have an effect on nearby
mouse gene expression. Additionally, the integration site is in an area of heterochromatin,
yet expression occurs in all erythroid cells. This demonstrates the integration siteindependent, high level erythroid expression that is associated with the LCR within
transgenic mice.130 Ultimately, the Berkeley mouse is left with a multi-integrated but
fully functional human transgene that successfully expresses human sickle adult
hemoglobin and faithfully recapitulates SCD.
The multi-integration of the human transgene, while a complication for reasons
related to chromatin silencing, has further implications for the purposes of gene editing.
Here, we demonstrate that on-target CRISPR/Cas9 gene editing of the repetitive
transgenic sequence causes significant DNA damage response and is extremely
detrimental to cell health. DSBs are one of the most toxic forms of DNA damage and
even a single DSB can lead to cell cycle arrest and an increase in p53 expression.103–105,123
In the case of gene editing in the Berkeley model, our strategy results in what could
amount to more than twenty DSBs in a single cell considering that TLA results estimated
ten or more copies of the transgene. We predict this effect, and the cascade of negative
cellular and molecular consequences that follow, will apply to many other transgenic
models as they are repurposed to test gene editing strategies. In fact, many groups may
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have already tested strategies and witnessed undesired results in the Berkeley mice,
abandoning projects altogether or moving to other models like the Townes or -YAC.131
Within this dissertation, initial Berkeley mouse Lin- culturing and embryo microinjection
were unsuccessful due to the nature of the multi-integrated transgenic model and the
CRISPR/Cas9 strategy being attempted. While multi-integrated transgenic models are
clearly useful for many purposes, our studies highlight an important limitation for gene
editing. It will be important for investigators to be cognizant of the limitations of such
models and use genomic characterization as a tool to better understand and interpret
results.
Furthermore, this scenario raises additional points regarding our ability to edit
repetitive elements. Editing in repetitive elements has already been associated with
heightened DNA damage.123,125 Given that more than half of the human genome is made
up of repetitive DNA, the likelihood of gene editing strategies for disease encountering
one of these repeated elements through on- or off-target DNA alterations is high.132 That
further stresses the need for strategies that improve the versatility of Cas9 endonucleases
and explores options for avoiding DSBs altogether. Technologies like base editing and
prime editing represent promising tools for editing of such repetitive elements and may
also prove to be useful in multi-integrated transgenic models, though this remains to be
tested.115,116

HbF Induction Strategies Are Likely Ineffective Due to Missing Cis-Regulatory
Elements in the Townes Knock-in Model
The Townes model is currently the most commonly used animal model for studies
of SCD pathology. After our findings in the Berkeley mouse, we measured DNA damage
after editing that was equivalent to that of controls. Next, we were able to move forward
to investigate whether Cas9 disruption of the BCL11A binding site in the human -globin
promoter in Townes mice can recapitulate effects of HPFH by inducing HbF and
ameliorating the effects of SCD. We showed that this genetic manipulation caused a
statistically significant induction in HbF. However, the magnitude of HbF induction was
approximately 10-fold less than what occurs in human cells, and therefore, inadequate for
improving hematological parameters that serve as biomarkers for SCD severity, such as
blood hemoglobin level and reticulocyte count.78 This result led us to further investigate
why a gene editing strategy previously shown in human cells to be a potent inducer of
HbF would not have the same effect in a widely used SCD mouse model.78,131,133
We thought that a more detailed mapping of the human knock-in may provide
explanations for our limited HbF induction and could only benefit future work in this
model. After confirming the presence of the HBG1 and HBBS sequences, we
acknowledged that important regulatory elements that have been identified since the
creation of the Townes model were missing from the knock-in sequence. Given the
conservation of the mouse and human globin loci, it is arguable that most human
elements that were not included within the knock-in would be compensated for by the
mouse locus. However, synteny analysis further suggested elements like BGLT3, a long
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noncoding RNA recently shown to enhance mediator-binding and increase γ-globin
expression, that are not conserved in the endogenous mouse locus may play important
roles in -like globin gene regulation.134 This may suggest that missing BGLT3 and other
sequences, while still allowing for HbF induction, prevents the high level of induction
seen in the human cell context.78
The explanation that missing regulatory elements are responsible for the lack of
HbF induction was further supported by recent publications that targeted the same HBG
promoter sequence using adenoviral vectors but in the -YAC mouse model.131 This
model includes the entirety of the -globin locus but does not harbor the SCD mutation
or phenotype, making it an excellent tool for studying hemoglobin regulation.135 In this
model, the same HBG promoter site was targeted with an adenoviral vector harboring
Cas9 and gRNA. Resulting -YAC transplantations showed equivalent editing but
increased -globin to >30% relative to -globin protein (compared to our 3-4% HbF).
This increase is comparable to that which is seen in human CD34+ cells; supporting the
hypothesis that additional genetic elements that are absent in the Townes model are
necessary for robust HbF induction.78,131 Not only does this further emphasize the
importance of the missing elements on hemoglobin regulation, but it will likely influence
the continued development of SCD models.
Finally, we note the possibility of a disconnect between mouse transcription
factors and human transcription factor binding sites, namely mouse BCL11A and the
binding site located at the human HBG promoter. Previously, mouse BCL11A has been
shown to successfully regulate the human locus within both the Berkeley and Townes
models when performing genetics crosses between the disease models and a Bcll1a
erythroid knockout model.97 However, other transcription factors both known and
unknown may further affect the regulation of the human sequence within the mouse
model.

Base Editing to Recreate the Hb G-Makassar Improves SCD Phenotype
Our studies in the Berkeley mouse have demonstrated the consequences of DSBinduced gene editing in HSCs that have multiple target sites. Fortunately, the toxicity
associated with even a single DSB from CRISPR/Cas9 editing has become the focus of
groups hoping to improve Cas9 endonucleases. One such technique is base editing, which
has shown great promise in binding to the target sequence and not creating DSBs, instead
using a nickase and deaminase to alter a single nucleotide.115,116 While there is currently
no base-editor capable of directly correcting the SCD mutation, it is possible to produce
an assumed benign hemoglobin variant, Hb G-Makassar (Glu6Ala).35 Given the
limitations of HbF induction strategies that we previously identified within the Townes
mouse model, we concluded that it would be better suited to study alterations of the SCD
mutation. Indeed, transplantation of base edited Townes HbSS Lin- cells to produce Hb
G-Makassar in erythroid progeny showed impressive editing, engraftment, and major
improvement of the mouse blood count values and organ pathologies.
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The use of base editing to convert HbS to Hb G-Makassar shows great promise as
a potentially therapeutic strategy in improving the SCD phenotype. While little is known
about this rare variant, patients that harbor the Makassar variant do not experience RBC
sickling or associated pathologies.33,34 Using the Townes model, we were able to
investigate the question of how much editing to generate Hb G-Makassar is sufficient for
phenotype improvement. By titrating different ratios of bone marrow from Makassarcorrected and non-corrected SCD Townes mice in secondary transplants, we showed that
there is a nonlinear base-editing dose-response of certain blood biomarkers for SCD.
Specifically, we showed that a Hb G-Makassar allele frequency of approximately 20% is
sufficient to fully correct SCD biomarkers, including hemoglobin levels, reticulocyte
count and white blood cell count. Similarly, it has been shown that 20% healthy donor
myeloid chimerism is sufficient to reverse sickling in SCD patients that receive allogenic
nonmyeloablative HSC transplants.136 This knowledge suggests that the Hb G-Makassar
base-editing strategy may be similar in effectiveness for correcting certain SCD
biomarkers.
While Townes mice expressing 80% HbG in RBCs exhibited apparent correction
of numerous SCD biomarkers, some disease parameters did not normalize to the values
observed in SCD heterozygous (HbAS) Townes mice. For example, HbAS Townes mice
had a normal spleen weight and no RBC sickling after exposure to 2% O2, while these
parameters remained slightly abnormal in Hb G-Makassar-edited mice. Single cell colony
forming unit (CFU) assays provided additional information as to the heterogeneity of
base editing. One could hypothesize that 2G2 tetramers would be more effective at
preventing hemoglobin polymerization than 2SG tetramers. CFU data showed
approximately 40:40:20 split for biallelic:monoallelic:unedited colonies from individual
mouse bone marrow Lin- cells. This finding of many monoallelic edited colonies may
explain lack of full correction, and hints that this is indeed an area of concern in the field
of editing.
In SCD, the electrostatic interactions that govern the formation of hemoglobin
tetramers indicates that a healthy, negative -globin (Glu) has an advantage over the less
negative S-globin (Val) when binding to a positive -globin.137–139 However, the G
Makassar globin (Ala) does not have a negative charge difference and prevents any sort
of competitive advantage over -globin. This could be an explanation for a lack of full
phenotype correction, or simply an advantage of HbA strategies over Hb G-Makassar.
Importantly, it is likely that even a partial improvement would be sufficient to improve a
patient’s disease prognosis though it does emphasize the need for more detailed study
into the pathogenesis of Hb G-Makassar and correlation of allelic editing to phenotypes.
For example, we can perform CFU assays on bone marrow Lin- cells to determine which
recipient mice have more biallelic editing and how their disease pathology has improved.
It would be interesting to determine if more biallelic editing resulted in the most
improved SCD phenotype, hinting that 2G2 tetramers may be more effective in
preventing sickling and other SCD-related RBC morphologies.
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New and Improved Disease Models
The findings of this dissertation amplify the importance of having a disease model
that best supports a therapeutic strategy. Simply, we show that DSB-induced gene editing
of the -globin promoter to recreate HPFH in the multi-integrated Berkeley transgene is
not possible because excessive Cas9-induced DSBs destroy HSCs. In contrast, it is
possible to disrupt the single copy -globin promoter BCL11A binding motif in Townes
mouse repopulating HSCs. However, this mutation does not induce HbF to the same
levels as it does in human cells. Our findings elucidating these limitations suggest some
approaches to improve mouse models for SCD. With recent technological advancements,
the creation of a model that harbors a single copy of a larger portion of the -globin locus
is a realistic and achievable goal should the field find the need for better SCD models.
Alternatively, variations of the previously validated mouse models (e.g. a second
generation knock-in on the Townes background) may be more well accepted by the
scientific community than development of entirely new mouse models because of the
extensive work already done in these mice. Further studies as to whether the presence of
BGLT3 is required for HbF induction remain. An updated Townes model could be
developed using homologous recombination and our described Townes knock-in
sequence to integrate in a functional copy of BGLT3. In this new model, experiments
repeating CRISPR/Cas9 targeting of the -globin promoter and measuring HbF induction
would determine if BGLT3 is indeed enough to enhance -globin expression to levels
comparable to the aforementioned human xenotransplantation studies.
Regardless of the future of SCD mouse models, it is our hope that this dissertation
provides insight into the capabilities and limitations of the often-utilized animal models
and paves the way for their improved use in the future. This dissertation does, however,
demonstrate a well-validated transplantation strategy that results in efficient engraftment
and the production of functional, edited RBCs in the peripheral blood. It presents
examples of the positive (high editing and phenotype improvement) and negative side
effects (chromosomal abnormalities, apoptosis, and p21 induction) of gene editing
strategies on preclinical models. Finally, it demonstrates significant phenotype
improvement after base editing mouse HSPCs to alter the SCD variant to an alternative
hemoglobin variant, although the exact pathophysiological effect remains to be
determined. In this dissertation, the Hb G-Makassar base editing strategy is an example
of what can be achieved after reevaluating the genomic characterization and
acknowledging the limitations of available models.
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APPENDIX. TOWNES CONSENSUS SEQUENCE

The consensus sequence of the 13.7kb fragment obtained by Oxford Nanopore
MinION sequencing is below. Highlighted portions indicate the following: HBB gene and
surrounding sequence, HBG1 gene and surrounding sequence, and mouse genome.
TTCTTTTCTACMTTCTTYCTACTTGGCTCCAGGCACATTCCCACATCAAGATA
AAGAGAAACAGGTATAGCTACATAGTCTCTACTTTTAGACAATCGAGTCTAC
TAATGTTTCAAAACATTGAGTTCTAAATAATTTTATACTGATTTCTATGTCTTT
AGAATTGAGATTTCTCCATTTGCATCTGCAGATCCCAAAAATTGAATAGAATC
ACTACTGCACAGGGTATGCTCAATTCAAATGTACCTTATTTTAAAACATTATT
TAGCTATGTGTAAAAGTGAAATAAAGAGGTAAGTTCACATACAAATAGAGAG
GCATACAAACATACATGCATACATACACATACATACATACATACATACATAC
ATACACACAGACTCACAGACACACAGATATACAGAGATACAGACACACAGA
GACACACACACAGGCACATATACAAATATACACACATACACATATTCACAGA
TATACAGAGATACAGACACACACTCAGAGACATACACATGGACATGCATACA
CACACACAGATATACACAGATACACACACACACATGGGCAGCATGTGCTGAG
GACTTGGTTCAGTAAATAAAGGTCAAGGCTGCCTGCCTTTAATTCAAAAGCG
TGGAAGACAGGACAATCCCTGAAAAAGCAGGTTATCCAAGCTAACCAGATTT
GTGAGCTCAGGGTTTACTTGAGAGATCCTGACTCAACAATAAGGTATAGAGC
AATCAAGGGCGATTCTCTGAAGGCAGTTATTGAACTCCTTGTACACTCTTCCC
ACACACACGTGTTCAGAGAACTTGATAAAACACATATATACAAGTAAGCCAC
ACAAACATTCACATGAGAGAAGAAAAACAAGAGCAAACTAAGTAAGATGCA
TTTTCTTATCAGGAAGTTTAGTTGACACCAGAAAGAAGTCATATTTGGAATCA
AAATGGAATCATCATCATGTATGCTAAAGATGTTTTTTTCACATTCTTGAGCA
ATGTGGACAGAGAAGGAGATTCATCCATGCACTCAAACTGGGAAACAAAGA
AAAGAAATCCTCTTCTAAGCTTATCGATKGGGGATCCTCTAGAGTCGATCGA
CCTCAGGCATGCAAGCTTTACACAGGATCATGAAGGATGAAAGAATTTCACC
AATATTATAATAATTTCAATCAACCTGATAGCTTAGGGGATAAACTAATTTGA
AGATACAGCTTGCCTCCGATAAGCCAGAATTCCAGAGCTTCTGGCATTATAAT
CTAGCAAGGTTAGAGATCATGGATCACTTTCAGAGAAAAACAAAAACAAACT
AACCAAAAGCAAAACAGAACCAAAAAACCACCATAAATACTTCCTACCCTGT
TAATGGTCCAATATGTCAGAAACAGCGCTGTGTTAGAAATAAAGCTGTCTAA
AGTACACTAATATTCGAGTTATAATAGTGTGTGGACTATTAGTCAATAAAAA
CAACCCTTGCCTCTTTAGAGTTGTTTTCCATGTACACGCACATCTTATGTCTTA
GAGTAAGATTCCCTGAGAAGTGAACCTAGCATTTATACAAGATAATTAATTC
TAATCCACAGTACCTGCCAAAGAACATTCTACCATCATCTTTACTGAGCATAG
AAGAGCTACGCCAAAACCCTGGGTCATCAGCCAGCACACACACTTATCCAGT
GGTAAATACACATCATCTGGTGTATACATACATACCTGAATATGGAATCAAA
TATTTTTCTAAGATGAAACAGTCATGATTTATTTCAAATAGGTACGGATAAGT
AGATATTGAGGTAAGCATTAGGTCTTATATTATGTAACACTAATCTATTACTG
CGCTGAAACTGTGGCTTTATAGAAATTGTTTTCACTGCACTATTGAGAAATTA
AGAGATAATGGCAAAAGTCACAAAGAGTATATTCAAAAAGAAGTATAGCAC
TTTTTCCTTAGAAACCACTGCTAACTGAAAGAGACTAAGATTTGTCCYGTCAA
AAATCCTGGACCTATGCCTAAAACACATTTCACAATCCCTGAACTTTTCAAAA
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ATTGGTACATGCTTTAGCTTTAAACTACAGGCCTCACTGGAGCTACAGACAA
GAAGGTAAAAAACGGCTGACAAAAGAAGTCCTGGTATCCTCTATGATGGGAG
AAGGAAACTAGCTAAAGGGAAGAATAAATTAGAGAAAAACTGGAATGACTG
AATCGGAACAAGGCAAAGGCTATAAAAAAAATTAGCAGTATCCTCTTGGGGG
CCCCTTCCCCACACTATCTCAATGCAAATATCTGTCTGAAACGGTCCCTGGCT
AAACTCCACCCATGGGTTGGCCAGCCTTGCCTTGACCAATAGCCTTGACAAG
GCAAACTTGACCAATAGTCTTAGAGTATCCAGTGAGGCCAGGGGCCGGCGGC
TGGCTAGGGATGAAGAATAAAAGGAAGCACCCTTCAGCAGTTCCACACACTC
GCTTCTGGAACGTCTGAGGTTATCAATAAGCTCCTAGTCCAGACGCCATGGGT
CATTTCACAGAGGAGGACAAGGCTACTATCACAAGCCTGTGGGGCAAGGTGA
ATGTGGAAGATGCTGGAGGAGAAACCCTGGGAAGGTAGGCTCTGGTGACCA
GGACAAGGGAGGGAAGGAAGGACCCTGTGCCTGGCAAAAGTCCAGGTTGCT
TCTCAGGATTTGTGGCACCTTCTGACTGTCAAACTGTTCTTGTCAATCTCACA
GGCTCCTGGTTGTCTACCCATGGACCCAGAGGTTCTTTGACAGCTTTGGCAAC
CTGTCCTCTGCCTCTGCCATCATGGGCAACCCCAAAGTCAAGGCACATGGCA
AGAAGGTGCTGACTTCCTTGGGAGATGCCATAAAGCACCTGGATGATCTCAA
GGGCACCTTTGCCCAGCTGAGTGAACTGCACTGTGACAAGCTGCATGTGGAT
CCTGAGAACTTCAAGGTGAGTCCAGGAGATGTTTCAGCCCTGTTGCCTTTAGT
CTCGAGGCAACTTAGACAACTGAGTATTGATCTGAGCACAGCAGGGTGTGAG
CTGTTTGAAGATACTGGGGTTGGGGGTGAAGAAACTGCAGAGGACTAACTGG
GCTGAGACCCAGTGGTAATGTTTTAGGGCCTAAGGAGCGCCTCTAAAAATCT
AGATGGACAATTTTGACTTTGAGAAAAGAGAGGTGGAAATGAGGAAAATGA
CTTTTCTTTATTAGATTCCAGTAGAAAGAACTTTCATCTTTCCCTCATTTTTGT
TGTTTTAAAACATCTATCTGGAGGCAGGACAAGTATGGTCGTTAAAAAGATG
CAGGCAGAAGGCATATATTGGCTCAGTCAAAGTGGGGAACTTTGGTGGCCAA
ACATACATTGCTAAGGCTATTCCTATATCAGCTGGACACATATAAAATGCTGC
TAATGCTTCATTACAAACTTATATCCTTTAATTCCAGATGGGGGCAAAGTATG
TCCAGGGGTGAGGAACAATTGAAACATTTGGGCTGGAGTAGATTTTGAAAGT
CAGCTCTGTGTGTGTGTGTGTGTGTGCGCGCGCGYGTGTGTGTGTGTGTGTCA
GCGTGTGTTTCTTTTAACGTCTTCAGCCTACAACATACAGGGTTCATGGTGGC
AAGAAGATAGCAAGATTTAAATTATGGCCAGTGACTAGTGCTTGAAGGGGAA
CAACTACCTGCATTTAATGGGAAGGCAAAATCTCAGGCTTTGAGGGAAGTTA
ACATAGGCTTGATTCTGGGTAGAAGCTKGGTGTGTAGTTATCTGGAGGCCAG
GCTGGAGCTCTCAGCTCACTATGGGTTCATCTTTATTGTCTCCTTTCATCTCAA
CAGCTCCTGGGAAATGTGCTGGTGACCGTTTTGGCAATCCATTTCGGCAAAG
AATTCACCCCTGAGGTGCAGGCTTCCTGGCAGAAGATGGTGACTGCAGTGGC
CAGTGCCCTGTCCTCCAGATACCACTGAGCTCTTTGCCCATGATTCAGAGCTT
TCAAGGATAGGCTTTATTCTGCAAGCAATACAAATAATAAATCTATTCTGCTG
AGAGATCACACATGATTTTCTTCAGCTCTTTTTTTTACATCTTTTTAAATATAT
GAGCCACAAAGGGTTTATATTGAGGGAAGTGTGTATGTGTATTTCTGCATGCC
TGTTTGTGTTTGTGGTGTGTGCATGCTCCTCATTTATTTTTATATGAGATGTGC
ATTTTGTTGAGCAAATAAAAGCAGTAAAGACACTTGTACACGGGAGTTCTGC
AAGTGGGAGTAAATGGTGTAGGAGAAATCCGGTGGGAAGAAAGACCTCTAT
AGGACAGGACTTCTCAGAAACAGATGTTTTGGAAGAGATGGGAAAAGGTTCA
GTGAAGACCTGGGGGCTGGATTGATTGCAGCTGAGTAGCAAGGATGGTTCTT
AATGAAGGGAAAGTGTTCCAAGSTCGAGGAATTCAAGGTTTAGTCAGGTGTA
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GCAATTCTATTTTATTAGGAGGAATACTATTTCTAATGGCACTTAGCTTTTCA
CAGCCCTTGTGGATGCCTAAGAAAGTGAAATTAATCCCATGCCCTCAAGTGT
GCAGATTGGTCACAGCATTTCAAGGGAGAGACCTCATTGTAAGACTCTGGGG
GAGGTGGGGACTTAGGTGTAAGAAATGAATCAGCAGAGGCTCACAAGTCAG
CATGAGCATGTTATGTCTGAGAAACAGACCAGCACTGTGAGATCAAAATGTA
GTGGGAAGAATTTGTACAACATTAATTGGAAGGTTTACTTAATGGAATTTTTG
TATAGTTGGATGTTAGTGCATCTCTATAAGTAAGAGTTTAATATGATGGTGTT
ACGGACCTAATGTTTGTGTCTCCTCAAAATTCACATGCTGAATCCCCAACTCC
CAACTGACCTTATCTGTGGGGGAGGCTTTTGAAAAGTAATTAGGTTTAGCTGA
GCTCATAAGAGCAGATCCCCATCATAAAATTATTTTCCTTATCAGAAGCAGA
GAGACAAGCCATTTCTCTTTCCTCCCGGTGAGGACACAGTGAGAAGTCCGCC
ATCTGCAATCCAGGAAGAGAACCCTGACCACGAGTCAGCCTTCAGAAATGTG
AGAAAAAACTCTGTTGTTGAAGCCACCCAGTCTTTTGTATTTTGTTATAGCAC
CTTACACTGAGTAAGGCAGATGAAGAAGGAGAAAAAAATAAGCTTGGGTTTT
GAGTGGACTACAGACCATGTTTATCTCAGGTTTGCAAAGCTCCCCTCGTCCCC
TATGTTTCAGTATAAAATACCTACTCTACTACTCTCATCTATAAGACCCAAAT
AATAAGCCTGCGCCCTTCTCTCTAACTTTGATTTCTCCTATTTTTACTTCAACA
TGCTTTACTCTAGCCTTGTAATGTCTTTACATACAGTGAAATGTAAAGTTCTTT
ATTCTTTTTTTCTTTCTTTCTTTTTTCTCCTCAGCCTCAGAATTTGGCACATGCC
CTTCCTTCTTTCAGGAACTTCTCCAACATCTCTGCCTGGCTCCATCATATCATA
AAGGTCCCACTTCAAATGCAGTCACTACYGTTTCAGAATATGCACTTTCTTTC
TTTTTTGTTTTTTGTTTTTTTTAAGTCAAAGCAAATTTCTTGAGAGAGTAAAGA
AATAAACGAATGACTACTGYATAGGCAGAGCAGCCCYGAGGGCCGCTGGTT
GTTCCTTTTATGGTTATTTCTTGATGATATGTTAAACAAGTTTTGGATTATTTA
TGCCTTCTCTTTTTAGGCCATATAGGGTAACTTTCTGACATTGCCATGGCATTT
TTCTTTTAATTTAATTTACTGTTACCTTAAATTCAGGGGTACACGTACAGGAT
ATGCAGGTTTGTTTTATAGGTAAAAGTGTGCCATGGTTTTAATGGGTTTTTTTT
TTCTTGTAAAGTTGTTTAAGTTTCTTGTTTACTCTGGATATTAGGCCTTTGTCA
GAAGAATAGATTGGAAAATCTTTTTCCCATTCTGTAGATTGTCTTTCGCTCTG
ATGGTAGTTTCTTTTGCTGAGCAGGAGCTCTTTAGTTTAATTAGATTCCATTG
GTCAATTTTTGCTTTTGCTGCAATTGCTTTTCACGCTTTCATCATGAAATCTGT
GCCCGTGTTTATATCATGAATAGTATTGCCTTGATTTTTTTCTAGGCTTTTTAT
AGTTTGGGGTTTTTCATTTAAGTCTCTAATCCATCTGGAGTTAATTTTGGATAA
GGTATAAGGAAGGAGTCCAGTTTCATTTTTCAGCATATGGCTAGCCAGTTCTC
CCCCATCATTTATTAAATTGAAAATCCTTTCCCCATTGCTTGCTTTTGTCAGGT
TTCTAAAAGACCAGATGGTTGTAGGTACAATATGCAGTTTCTTCAAGTCATAT
AATACCATCTGAAATCTCTTATTAATTCATTTCTTTTAGTATGTATGCTGGTCT
CCTCTGCTCACTATAGTGAGGGCACCATTAGCCAGAGAATCTGTCTGTCTAGT
TCATGTAAGATTCTCAGAATTAAGAAAAATGGATGGCATATGAATGAAACTT
CATGGATGACATATGGAATCTAATATGTATTTGTTGAATTAATGCATAAGATG
CAACAGGGAGAAGTTGACAACTGCAATGATAACCTGGTATTGATGATATAAG
AGTCTATAGATCACAGTAGAAGCAATAATCATGGAAAACAATTGGAAATGGG
GAACAGCCACAAACAAGAAAGAATCAATACTTCCAGGAAAGTGACTGCAGG
TCACTTTTCCTGGAGCGGGTGAGAGAAAAGTGGAAGTTAGCAGTAACTGCTG
AATTCTCGGATCCTCAGAGTCGAGGAATTGRGCTCCCCTAACCTCCTATTTGA
CACCACTGATTACCCCATTGATAGTCACACTTTGGGTTGTAAGTGACTTTTTA
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TTTATTTGTATTTTTGACTGCATTAAGAGGTCTCTAGTTTTTTATCTCTTGTTTC
CCAAAACCTAATAAGTAACTAATGCACAGAGCACATTGATTTGTATTTATTCT
ATTTTTAGACATAATTTATTAGCATGCATGAGCAAATTAAGAAAAACAACAA
CAAATGAATGCATATATATGTATATGTATGTGTGTATATATACACATATATAT
ATATATWTTTTTTCTTTTCTTACCAGAAGGTTTTAATCCAAATAAGGAGAAGA
TATGCTTAGAACTGAGGTAGAGTTTTCATCCATTCTGTCCTGTAAGTATTTTG
CATATTCTGGAGACGCAGGAAGAGATCCATCTACATATCCCAAAGCTGAATT
ATGGTAGACAAAACTCTTCCACTTTTAGTGCATCAACTTCTTATTTGTGTAAT
AAGAAAATTGGGAAAACGATCTTCAATATGCTTACCAAGCTGTGATTCCAAA
TATTACGTAAATACACTTGCAAAGGAGGATGTTTTTAGTAGCAATTTGTACTG
ATGGTATGGGGCCAAGAGATATATCTTAGAGGGAGGGCTGAGGGTTTGAAGT
CCAACTCCTAAGCCAGTGCCAGAAGAGCCAAGGACAGGTACGGCTGTCATCA
CTTAGACCTCACCCTGTGGAGCCACACCCTAGGGTTGGCCAATCTACTCCCAG
GAGCAGGGAGGGCAGGAGCCAGGGCTGGGCATAAAAGTCAGGGCAGAGCCA
TCTATTGCTTACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAAC
AGACACCATGGTGCACCTGACTCCTGTGGAGAAGTCTGCCGTTACTGCCCTGT
GGGGCAAGGTGAACGTGGATGAAGTTGGTGGTGAGGCCCTGGGCAGGTTGGT
ATCAAGGTTACAAGACAGGTTTAAGGAGACCAATAGAAACTGGGCATGTGG
AGACAGAGAAGACTCTTGGGTTTCTGATAGGCACTGACTCTCTCTGCCTATTG
GTCTATTTTCCCACCCTTAGGCTGCTGGTGGTCTACCCTTGGACCCAGAGGTT
CTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAACCCTA
AGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGC
TCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGT
GACAAGCTGCACGTGGATCCTGAGAACTTCAGGGTGAGTCTATGGGACCCTT
GATGTTTTCTTTCCCCTTCTTTTCTATGGTTAAGTTCATGTCATAGGAAGGGGA
GAAGTAACAGGGTACAGTTTAGAATGGGAAACAGACGAATGATTGCATCAGT
GTGGAAGTCTCAGGATCGTTTTAGTTTCTTTTATTTGCTGTTCATAACAATTGT
TTTCTTTTGTTTAATTCTTGCTTTCTTTTTTTTTCTTCTCCGCAATTTTTACTATT
ATACTTAATGCCTTAACATTGTGTATAACAAAAGGAAATATCTCTGAGATAC
ATTAAGTAACTTAAAAAAAAACTTTACACAGTCTGCCTAGTACATTACTATTT
GGAATATATGTGTGCTTATTTGCATATTCATAATCTCCCTACTTTATTTTCTTT
TATTTTTAATTGATACATAATCATTATACATATTTATGGGTTAAAGTGTAATG
TTTTAATATGTGTACACATATTGACCAAATCAGGGTAATTTTGCATTTGTAAT
TTTAAAAAATGCTTTCTTCTTTTAATATACTTTTTTGTTTATCTTATTTCTAATA
CTTTCCCTAATCTCTTTCTTTCAGGGCAATAATGATACAATGTATCATGCCTCT
TTGCACCATTCTAAAGAATAACAGTGATAATTTCTGGGTTAAGGCAATAGCA
ATATTTCTGCATATAAATATTTCTGCATATAAATTGTAACTGATGTAAGAGGT
TTCATATTGCTAATAGCAGCTACAATCCAGCTACCATTCTGCTTTTATTTTATG
GTTGGGATAAGGCTGGATTATTCTGAGTCCAAGCTAGGCCCTTTTGCTAATCA
TGTTCATACCTCTTATCTTCCTCCCACAGCTCCTGGGCAACGTGCTGGTCTGTG
TGCTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTGCCTAT
CAGAAAGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAG
CTCGCTTTCTTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCA
ACTACTAAACTGGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCT
AATAAAAAACATTTATTTTCATTGCAATGATGTATTTAAATTATTTCTGAATA
TTTTACTAAAAAGGGAATGTGGGAGGTCAGTGCATTTAAAACATAAAGAAAT
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GAAGAGCTAGTTCAAACCTTGGGAAAATACACTATATCTTAAACTCCATGAA
AGAAGGTGAGGCTGCAAACAGCTAATGCACATTGGCAACAGCCCCTGATGCC
TATGCCTTATTCATCCCTCAGAAAAGGATTCAAGTAGAGGCTTGATTTGGAGG
TTAAAGTTTTGCTATGCTGTATTTTACATTACTTATTGTTTTAGCTGTCCTCAT
GAATGTCTTTTCACTACCCATTTGCTTATCCTGCATCTCTCAGCCTTGACTCCA
CTCAGTTCTCTTGCTTAGAGATACCACCTTTCCCCTGAAGTGTTCCTTCCATGT
TTTACGGCGAGATGGTTTCTCCTCGCCTGGCCACTCAGCCTTAGTTGTCTCTGT
TGTCTTATAGAGGTCTACTTGAAGAAGGAAAAACAGGGGGCATGGTTTGACT
GTCCTGTGAGCCCTTCTTCCCTGCCTCCCCCACTCACAGTGACCCGGAATCTG
CAGTGCTAGTCTCCCKGAACTATCACTCTTTCACAGTCTGCTTTGGAAGGACT
GGGCTTAGTATGAAAAGTTAGGACTGAGAAGAATTTGAAAGGGGGCTTTTTG
TAGCTTGATATTCACTACTGTCTTATTACCCTATCATAGGCCCACCCCAAATG
GAAGTCCCATTCTTCCTCAGGATGTTTAAGATTAGCATTCAGGAAGAGATCA
GAGGTCTGCTGGCTCCCTTATCATGTCCCTTATGGTGCTTCTGGCTCTGCAGTT
ATTAGCATAGTGTTACCATCAACCACCTTAACTTCATTTTTCTTATTCAATACC
TAGGTAGGTAGATGCTAGATTCTGGAAATAAAATATGAGTCTCAAGTGGTCC
TTGTCCTCTCTCCCAGTCAAATTCTGAATCTAGTTGGCAAGATTCTGAAATCA
AGGCATATAATCAGTAATAAGTGATGATAGAAGGGTATATAGAAGAATTTTA
TTATATGAGAGGGTGAAACCCTCAAAATGAAATGAAATCAGACCCTTGTCTT
ACACCATAAACAAAAATAAATTTGAATGGGTTAAAGAATTAAACTAAGACCT
AAAACCATAAAAATTTTTAAAGAAATCAAAAGAAGAAAATTCTAATATTCAT
GTTGCAGCYGTTTTTTGAATTTGATATGAGAAGCAAAGGCAACAAAAGGAAA
AATAAAGAAGTGAGGCTACATCAAACTAAAAAATTTCCACACAAAAAAGAA
AACAATGAACAAATGAAAGGTGAACCATGAAATGGCATATTTGYAAACYAA
ATATTTCTTAAATATTTTGGTTAATATCCAAAATATATAAGAAACACAGATGA
TTCAATAACAAACAAAAAATTAAAAATAGGAAAATAAAAAAATTAAAAAGA
AGAAAATCCTGCCATTTATGGCAGAATTGATGAACCTGGAGGATGTAAAACT
AAGAAAAATAAGCCTGACACAAAAAGACAAATACTACACAACCTTGCTCATA
TGTGAAACATAAAAAAGTCACTCTCATGGAAACAGACAGTAGAGGTATGGTT
TCCAGGGGTTGGGGGTGGGAGAATCAGGAAACTATTACTCAAAGGGTATAAA
ATTTCAGTTATGTGGGATGAATAAATTCTAGAGTCGAGCGCCGTATCGATAA
GCTTGATATCGAATTCCTGCAGATAACTTCGTATAATGTATGCTATACGAAGT
TATGGATCCACTAGTTCTAGAGCGGCCCGATAAGCTTGATATCGAATTCTGCA
GCCCGGGATCCTGAGAACTTCAGGGTGAGTCTGATGGGCACCTCCTGGGTTT
CCTTCCCCTGGCTATTCTGCTCAACCTTCCTATCAGAAGGAAAGGGGAAGCG
ATTCTAGGGAGCAGTTTCGATGATGGTGTGTGGATGTGAATTGTGGAGTGTTG
ACTAGAGTTTGGATATTTTATTCTCTACTCAGAATTGCTGCTCCCTCTCACTCT
GTTCTGTTCTTCTGTGTTGTCATTTCCTCTTTCTTGGTTAAGTTTTAATTTTCAG
TTGCAGTTTTAAAGTGCATCTTTTATCTACTTTCTGTTTTCTTTTCAAATATATC
CTGGTATCTTACTCTGAGGACAAAAAGATAAATGATTCTCTGATCCTTTCCAC
AGTTCTAATGAATTATAGGGCGATAATTGGCTTTTAGGATAGGACAATAAGG
AAGAGTATATTTTGTGGCTAAATTTTGTGTGTCATAGAATAATTCTTTTTTATT
TTTTATTTATTATTTTTTTCATAGAATAATTCTTATCAAAATTGACCAGTAGAA
CCCAGCTGCCATTTTACCTATCTTTGAAGATTATAACTGTAAATTCCATTTGA
AATCGGCCTTCAGCATCTTGTATTGTTGCTCTACTTCATATTGATGCGTCTTCT
GTCTTCCCACAGCTCCTGGGCAATGCGATCGTGATTGTGCTGGGCCACCACCT
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GGGCAAGGATTTCACCCCTGCTGCACAGGCTGCCTTCCAGAAGGTGGTGGCT
GGAGTGGCCACTGCCCTGGCTCACAAGTACCACTAAGCCCCTTTTCTGCTATT
GTCTATGCACAAAGGTTATATGTCCCCTAGAGAAAAACTGTCAAGTGTGGGG
AAATGATGAAGACCTTTGGGCATCTAGCTTTTATCTAATAAATGATATTTACT
GTCATCTCAATTCTGTGTTTTGATTACTTGTGTTTCTTGCAAGGATTAATGTGA
AATATTTATTATATAAAGCAGTTGGGGCATGCTGGAGGGATGGAAGTGAGGG
TAAAAGTCATGTCATTCTATTTCAGTTAAAACCATTCAAGAATAAAATACCAA
AGAAGAAGTGAGAGTTCAGAAACAAGGTATTCACTTTGACTTCCTGGTAATT
GACTTCTGCAGCTTTGTGATAAGTGGTGAGATAGTAAGTGGCTATTCTGTCAG
CAACCTTCCCTGACATCCATTTCTCAGAAAAAGAAGTCAAATAGGGGTTTAA
TTTACAGCATAGACATATACTATGCTTTATAGTTTTTTGTATTTTTCTAATTTT
TCCTCACAAATGCCCCTTGATTTTCTGCTTGTTGTCTAGTATCTCAGAGACTTC
AGTCTAATTTCTCTTGCCTCAAGTATCCATCACTCTTTTCTTTTATCTATCTATC
TATCTATCTATCTATCTATCTATCTAAAATATATATCAAATATATTTTTCTTTT
TTATTATTTTCTTTATTTACATTTCAAATGTTATCCCCTTTCCTAGTTTCCCCTC
CAAAAATCCCCTATCCCCTCTCCCCTCCCCCTGCTCCCCAACCCACCCACTCC
CATTCCTGGTCCTGGCATTTCCCTATATTGGGGCGTAGAGCCTTCACAGGACC
AAGGGCCCTGATTACTATTCAAGGGTGTCTTCCTTGCTTGCTTTTCTATGAAC
ATTATCCATTTTCTCCTGACCTCTGTTATCTTAGAAAACCCCACTGTGTTACAG
AGATATGCTTGAAGAGGAAACCCAGGAGTTCTTGAGCCCTGGTCCCCAGCCT
CTCCCATTAACAATGATAATGAAACTTCACATACTCACAACTTGAACTAGAG
AACAGGAGGCATTAGTAAGGGGTAAATAAGGACTATGGAAAATATGAGCAG
AAATGTTTTGTTCTTTGATAGCCTTTGCAGACATAGGAAGCTTTCATGGGCTC
ATAGCAAAGAGAAGTCCATTTCCCCCAGTGTGTCTGTCTTGAATATCCACTAA
GGAGATGGAGATTGGACTCTCTCTGGACTGGTCTCTGTTGTTTCCCCTCCTGG
TTTTGTAATTGTTTGTATTATTCTTGGCAACACTTCATGTTCACAGTTTCCCAC
TCTTTAAGCACTTGTCTCATGCTAAATTCTGGAGACAAAATATGACTTTCAAG
TGTTCCTTATCCTGAACTACAAGGCAATGTTGTTAGAGTAATACATATGATAC
ATATGAATAGTTAGAGACCAATTATGAGATTACAGGATAAAGCCATCAAAAT
GAAATCAAATTAAACCATCACCTTAAACTCAAAAACAAACCAAAGCCTTAAG
ATATAAAAGTGCAAAATATCTAGAATGAAAAGAAGAGCAAAATTTATTAATA
TTGGCTGTGAACCAGGTTTGTAGTGCATGCCTGTGTTGCCAGCCCTCGAGAAC
CTGAGGCACAACCATAAAGTCTGCCTAGGATACACGGTGAAAGGTTTGTTTT
AATAGACAACAGCCACATTCAACATTTTAAAGGAAAAGCTCAGATAAGAAG
GACAAAAATGGACAAGTCAAATGTGACTAATAAAGTTTTTGCATAGCACGGA
GAATAATCAACAAAATGATAGTTAATTTAAAATGGGAGAAAGTATTTGTGAA
CTAAAATCCAACAGTGGATTACTATGCAAAGTGTGTAAGGAACCCATGCAAC
CCACTAGAAAGAACATGGAACACTAAAAGG
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